

## منابع

1. Sataloff J, Sataloff RT, Vassallo LA. Hearing Loss, Second Edition. Philadelphia, PA: J.B. Lippincott; 1980.
2. Sataloff RT, Sataloff J. Occupational Hearing Loss. New York, NY: Marcel Dekker; 1987.
3. Sataloff RT, Brandfonbrener A, Lederman R, eds. Textbook of Performing Arts Medicine. New York, NY: Raven Press; 1991.
4. Sataloff RT. Embryology and Anomalies of the Facial Nerve. New York, NY: Raven Press; 1991.
5. Sataloff RT. Professional Voice: The Science and Art of Clinical Care. New York, NY: Raven Press; 1991.
6. Sataloff RT, Titze IR, eds. Vocal Health & Science. Jacksonville, FL: The National Association of Teachers of Singing; 1991.
7. Gould WJ, Sataloff RT, Spiegel JR. Voice Surgery. St. Louis, MO: CV Mosby Co; 1993.
8. Sataloff RT, Sataloff J. Occupational Hearing Loss, 2nd ed. New York, NY: Marcel Dekker; 1993.
9. Mandel S, Sataloff RT, Schapiro S, eds. Minor Head Trauma: Assessment, Management and Rehabilitation. New York, NY: Springer-Verlag; 1993.
10. Sataloff RT, Sataloff J. Hearing Loss, 3rd ed. New York, NY: Marcel Dekker; 1993.
11. Rubin J, Sataloff RT, Korovin G, Gould WJ. Diagnosis and Treatment of Voice Disorders. New York, NY: IgakuShoin Medical Publishers, Inc; 1995.
12. Sataloff RT. Professional Voice: The Science and Art of Clinical Care, 2nd ed. San Diego, CA: Singular Publishing Group, Inc; 1997.
13. Rosen DC, Sataloff RT. Psychology of Voice Disorders. San Diego, CA: Singular Publishing Group, Inc; 1997.
14. Sataloff RT, Brandfonbrener A, Lederman R, eds. Performing Arts Medicine, 2nd ed. San Diego, CA: Singular Publishing Group, Inc; 1998.
15. Sataloff RT, 2nd ed. Vocal Health and Pedagogy. San Diego, CA: Singular Publishing Group, Inc; 1998.

16. Sataloff RT, ed. *Voice Perspectives*. San Diego, CA: Singular Publishing Group, Inc; 1998.
17. Sataloff RT, Castell DO, Katz PO, Sataloff DM. *Reflux Laryngitis and Related Disorders*. San Diego, CA: Singular Publishing Group, Inc; 1999.
18. Sataloff RT, Hawkshaw MJ, Spiegel JR. *Atlas of Laryngoscopy*. San Diego, CA: Singular Publishing Group, Inc; 2000.
19. Smith B, Sataloff RT. *Choral Pedagogy*. San Diego, CA: Singular Publishing Group, Inc; 2000.
20. Sataloff RT, Hawkshaw MJ. *Chaos in Medicine*. San Diego, CA: Singular Publishing Group, Inc; 2000.
21. Manon-Espaillet R, Heman-Ackah YD, Abaza M, Sataloff RT, Mandel S. *Laryngeal Electromyography*. Albany, NY: Singular Publishing Group; 2002.
22. Rubin JS, Sataloff RT, Korovin GS. *Diagnosis and Treatment of Voice Disorders*, 2nd ed. Albany, NY: Delmar Thomson Learning; 2003.
23. Sataloff RT, Castell DO, Katz PO, Sataloff DM. *Reflux Laryngitis and Related Disorders*, 2nd ed. Albany, NY: Delmar Thomson Learning; 2003.
24. Sataloff RT. *Professional Voice: The Science and Art of Clinical Care*, 3rd ed. San Diego, CA: Plural Publishing, Inc; 2005.
25. Sataloff RT, Sataloff J. *Hearing Loss*, 4th ed. New York, NY: Taylor & Francis, Inc; 2005.
26. Sataloff RT, ed. *Voice Science*. San Diego, CA: Plural Publishing, Inc; 2005.
27. Sataloff RT, ed. *Clinical Assessment of Voice*. San Diego, CA: Plural Publishing, Inc; 2005.
28. Sataloff RT, ed. *Treatment of Voice Disorders*. San Diego, CA: Plural Publishing, Inc; 2005.
29. Sataloff RT, Smith B. *Choral Pedagogy*, 2nd ed. San Diego, CA: Plural Publishing, Inc; 2006.
30. Sataloff, R.T, Mandel S, Heman-Ackah YD, ManonEspaillet R, Abaza, M. *Laryngeal Electromyography*, 2nd ed. San Diego, CA: Plural Publishing, Inc; 2006.
31. Sataloff RT, Sataloff J. *Occupational Hearing Loss*, 3rd ed. New York, NY: Taylor & Francis, Inc; 2006.
32. Sataloff RT, ed. *Vocal Health and Pedagogy*, 2nd ed. San Diego, CA: Plural Publishing, Inc; 2006.

33. Sataloff RT, Castell DO, Katz PO, Sataloff DM. Reflux Laryngitis and Related Disorders, 3rd ed. San Diego, CA: Plural Publishing, Inc; 2006.
34. Rubin J, Sataloff RT, Korovin G. Diagnosis and Treatment of Voice Disorders, 3rd ed. San Diego, CA: Plural Publishing, Inc; 2006.
35. Sataloff RT, Hawkshaw MJ, Eller R. Atlas of Laryngoscopy, 2nd ed. San Diego, CA: Plural Publishing, Inc; 2006.
36. Sataloff RT, Dentchev D, Hawkshaw MJ. Tinnitus. San Diego, CA: Plural Publishing, Inc; 2007.
37. Han D, Sataloff RT, Xu W, eds. Voice Medicine. Beijing, China: People's Medical Publishing House; 2007.
38. Sataloff RT, Chowdhury F, Joglekar SS, Hawkshaw MJ. Atlas of Endoscopic Laryngeal Surgery. New Delhi, India: Jaypee Brothers Medical Publishers; 2010.
39. Sataloff RT, Brandfonbrener A, Lederman R, eds. Performing Arts Medicine, 3rd ed. Narberth, PA: Science and Medicine; 2010.
40. Smith B, Sataloff RT. Choral Pedagogy and the Older Singer. San Diego, CA: Plural Publishing, Inc; 2012.
41. Sataloff RT, Hawkshaw MJ, Sataloff JB, DeFatta RA, Eller RL. Atlas of Laryngoscopy, 3rd ed. San Diego, CA: Plural Publishing, Inc; 2012.
42. Heman-Ackah YD, Sataloff RT, Hawkshaw MJ. The Voice: A Medical Guide for Achieving and Maintaining a Healthy Voice. Narberth, PA: Science and Medicine; 2013.
43. Sataloff RT, Katz PO, Sataloff DM, Hawkshaw MJ. Reflux Laryngitis and Related Disorders, 4th ed. San Diego, CA: Plural Publishing, Inc; 2013.
44. Smith B, Sataloff RT. Choral Pedagogy, 3rd ed. San Diego, CA: Plural Publishing, Inc; 2013.
45. Sataloff RT, Chowdhury F, Portnoy J, Hawkshaw MJ, Joglekar S. Surgical Techniques in Otolaryngology–Head and Neck Surgery: Laryngeal Surgery. New Delhi, India: Jaypee Brothers Medical Publishers; 2013.
46. Sataloff RT. Medical Musings. United Kingdom: Compton Publishing, Ltd; 2013.
47. Sataloff RT, Hawkshaw MJ, Moore JE, Rutt AL. 50 Ways to Abuse Your Voice: A Singer's Guide to a Short Career. United Kingdom: Compton Publishing, Ltd; 2014.

48. Rubin J, Sataloff RT, Korovin G. *Diagnosis and Treatment of Voice Disorders*, 4th ed. San Diego, CA: Plural Publishing, Inc; 2014.
49. Sataloff RT, Sataloff J. *Embryology and Anomalies of the Facial Nerve*, 2nd ed. New Delhi, India: Jaypee Brothers Medical Publishers; 2014.
50. Sataloff RT, Johns MM, Kost KM, eds. *Geriatric Otolaryngology*. Thieme Medical Publishers and the American Academy of Otolaryngology–Head and Neck Surgery; 2015.
51. Sataloff RT, ed. *Surgical Techniques in Otolaryngology– Head and Neck Surgery* (6 Volumes). New Delhi, India: Jaypee Brothers Medical Publishers; 2015.
52. Sataloff RT, ed. *Sataloff’s Comprehensive Textbook of Otolaryngology–Head and Neck Surgery* (6 Volumes). New Delhi, India: Jaypee Brothers Medical Publishers; 2015.
53. Moore JE, Hawkshaw MJ, Sataloff RT. *Vocal Fold Scar*. United Kingdom: Compton Publishing, Ltd; (In press).
54. Sataloff RT. *Professional Voice: The Science and Art of Clinical Care*, 4th ed. San Diego, CA: Plural Publishing, Inc; 2017.
55. Sataloff RT, ed. *Voice Science*, 2nd ed. San Diego, CA: Plural Publishing, Inc; 2017.
56. Sataloff RT, ed. *Clinical Assessment of Voice*, 2nd ed. San Diego, CA: Plural Publishing, Inc; 2017.
57. Sataloff RT, ed. *Treatment of Voice Disorders*, 2nd ed. San Diego, CA: Plural Publishing, Inc; 2017.
58. Sataloff RT, ed. *Vocal Health and Pedagogy*, 3rd ed. San Diego, CA: Plural Publishing, Inc; 2017.
59. Han D, Sataloff RT, Xu W, eds. *Voice Medicine*, 2nd ed. Beijing, China: People’s Medical Publishing House; (In press).

## فصل ١

1. Sataloff RT. Professional singers: the science and art of clinical care. *Am J Otolaryngol*. 1981;2(3):251–266.
2. Sataloff RT. The professional voice. In: Cummings CW, Frederickson JM, Harker LA, et al, eds. *Otolaryngology — Head and Neck Surgery*. Vol 3. St Louis, MO: CV Mosby; 1986:2029–2056.

3. Sataloff RT. Professional Voice: The Science and Art of Clinical Care. New York, NY: Raven Press; 1991.
4. Emerich KA, Baroody MM, Carroll LM, Sataloff RT. The singing voice specialist. In: Sataloff RT, ed. Professional Voice: The Science and Art of Clinical Care. 2nd ed. San Diego, CA: Singular Publishing Group; 1997: 735–753.
5. Freed SL, Raphael BN, Sataloff RT. The role of the acting-voice trainer in medical care of professional voice users. In: Sataloff RT, ed. Professional Voice: The Science and Art of Clinical Care. 2nd ed. San Diego, CA: Singular Publishing Group; 1997:765–774.

## فصل ۲

ندارد

## فصل ۳

1. California Speech Pathologists and Audiologists Licensure Act, Chapter 5.3, Division 2 of the Business and Professions Code, as cited in Flower R. Delivery of Speech Language Pathology and Audiology Services. Baltimore, MD: Williams & Wilkins; 1984:6.

## فصل ۴

1. Eckel FC, Boone DR. The S/Z ratio as an indication of laryngeal pathology. J Speech Hear Disord. 1981;46: 147–149.
2. Colton RH, Casper JK, Leonard R. Understanding Voice Problems: A Physiological Perspective for Diagnosis and Treatment. 4th ed. Lippincott, Williams and Wilkins; 2011: 339–340.
3. Verdolini K. Resonant Voice Therapy. National Center for Voice and Speech's Guide to Vocology. Iowa City, IA: National Center for Voice and Speech; 1998:34–35.
4. Stemple J, Hapner ER. Voice Therapy: Clinical Case Studies. 4th ed. San Diego, CA: Plural Publishing; 2014: 142–157.
5. Guzman M, Laukkanen AM, Krupa P, Horáčěk J, Švec JG, Geneid A. Vocal tract glottal function during and after vocal exercising with resonance tube and straw. J Voice. 2013;27(4):523.e19–523.e34.

6. Titze I. Voice training and therapy with a semi occluded vocal tract: Rational and scientific underpinnings. *J Speech Lang Hear Res.* 2006;49:448–459.
7. Stemple JC, Glaze LE, Gerdeman KB. *Clinical Voice Pathology: Theory and Management.* 4th ed. San Diego, CA: Plural Publishing; 2010. Ch. 7.
8. Johnson JA, Pring TR. Speech therapy and Parkinson's disease: a review and further data. *Br J Disord Commun.* 1990;25:183–194.
9. Ramig LO, Mead C, Scherer RC, Horii Y, Larson K, Kholer D. Voice therapy and Parkinson's disease: a longitudinal study of efficacy. Paper presented at the Clinical Dysarthria Conference; 1988; San Diego, CA.
10. Ramig LO. Speech therapy for Parkinson's disease. In: Koller WC, Paulson G, eds. *Therapy of Parkinson's Disease.* New York, NY: Marcel Dekker; 1995:539–550.
11. Ramig LO, Bonitati CM, Lemke JH, Horii Y. Voice treatment for patients with Parkinson's disease: development of an approach and preliminary efficacy data. *J Med Speech Lang Pathol.* 1994;2:191–209.
12. Ramig LO, Scherer RC. Speech therapy for neurologic disorders of the larynx. In: Blitzer A, Brin MF, Sasaki CT, Fahn S, Harris KH, eds. *Neurologic Disorders of the Larynx.* New York, NY: Thieme; 1992:163–181.
13. Roy N, Bless DM, Heisey D, Ford CN. Manual circumlaryngeal therapy for functional dysphonia: an evaluation of short and long term treatment outcomes. *J Voice.* 1997;3:321–331.
14. Alexander FM, McGowen D, eds. *Alexander Technique: Original Writings of FM Alexander: Constructive Conscious Control.* New York, NY: Larson Publications; 1997.
15. Coinable B, Coinable W. *How to Learn the Alexander Technique: A Manual for Students.* Columbus, OH: Andover Road Press; 1992.
16. Feldenkrais M. *Body and Mature Behavior: A Study of Anxiety, Sex, Gravitation and Learning.* New York, NY: International Universities Press 1950; 1980.
17. Feldenkrais M. *Awareness Through Movement: Health Exercises for Personal Growth.* New York, NY: Harper & Row; 1972.
18. Feldenkrais M. *The Elusive Obvious.* Cupertino, CA: Meta Publications; 1981.
19. Feldenkrais M. *The Potent Self: A Guide to Spontaneity.* New York, NY: Harper & Row; 1985.

20. Boone D. *The Voice and Voice Therapy*. Englewood Cliffs, NJ: Prentice Hall; 1983.
21. Froeschels E. Chewing method as therapy. *Arch Otolaryngol*. 1952;56:427–434.

## فصل ۵

1. Behrman A, Sulica L. Voice rest after microlaryngoscopy: current opinion and practice. *Laryngoscope*. 2003; 113(12):2182–2186.
2. Hoover CA, Sataloff RT, Lyons KM, Hawkshaw M. Vocal fold mucosal tears: maintaining a high clinical index of suspicion. *J Voice*. 2001;15:451–455.
3. Cho SH, Kim HT, Lee IJ, et al. Influence of phonation on basement membrane zone recovery after phonomicrosurgery: a canine model. *Ann Otol Rhinol Laryngol*. 2000;109:658–666.
4. Mitchell JR, Kojima T, Wu H, Garrett CG, Rousseau B. Biochemical basis of vocal fold mobilization after microflap surgery in a rabbit model. *Laryngoscope*. 2014; 124(2):487–498.
5. Verdolini K, Li NY, Branski RC, Rosen CA, Grillo E, Steinhauer K, Hebda PA. Vocal exercise may attenuate acute vocal fold inflammation. *J Voice*. 2012;26(6):814. e1–13.
6. Wong DLH, Adams SG, Irish JC, et al. Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia. *J Otolaryngol*. 1995; 24(4):209–221.
7. Arnstein DP, Berke GS, Trapp TK, Natividad M. Regional blood flow to the canine vocal fold at rest and during phonation. *Ann Otol Rhinol Laryngol*. 1989;98: 796–802.
8. Solomon NP, McCall GN, Trosset MW, Gray WC. Laryngeal configuration and constriction during two types of whispering. *J Speech Hear Res*. 1989;32:161–174.
9. Emerich KA, Spiegel JR, Sataloff RT. Phonomicrosurgery III: pre- and post-operative care. *Otolaryngol Clin North Am*. 2000;33:1071–1080.
10. Broaddus-Lawrence PL, Treole K, McCabe RB, et al. The effects of preventive vocal hygiene education on the vocal hygiene habits and perceptual vocal characteristics of training singers. *J Voice*. 2000;14:58–71.
11. Rubin AD, Praneetvatakul V, Gherson S, Moyer CA, Sataloff RT. Laryngeal hyperfunction during whispering: reality or myth? *J Voice*. 2006;20(1):121–127.



12. Murray T, Rosen CA. Vocal education for the professional voice user and singer. *Otolaryngol Clin North Am.* 2000;33:967–981.

## فصل ٦

1. Barton R, Rocco DV. *Voice: Onstage and Off.* Orlando, FL: Harcourt Brace College Publishers; 1995. (An accompanying CD is available as well.)
2. Eisenson J. *Voice and Diction: A Program for Improvement.* 7th ed. New York, NY: Macmillan; 1996.
3. Rodenburg P. *The Right to Speak.* New York, NY: Routledge; 1993.
4. Executive Performance Intraining Center (EPIC), Philadelphia, PA.

## فصل ٧

1. Berard JB, Murray S, trans-ed. *L'Art du chant.* Milwaukee, WI: Pro Music Press; 1969.
2. Mancini G, Foreman R, trans. *Practical Reflections on Figured Singing.* Champaign, IL: Pro Music Press; 1967.
3. Garcia M. *A Complete Treatise on the Art of Singing, Part One.* New York: Da Capo Press; 1983.
4. Titze I. Instrumentation for voice research. *NATS Bull.* 1983;38(5):29.
5. Bartholomew WT. *The Role of Imagery in Voice Teaching.* Proceedings of the Music Teachers National Association; 1935.
6. Abraham L. Sports biomechanics: application of high tech to Olympic engineering. *Tex Prof Engineer.* 1984; July–August:16–19.

## فصل ٨

1. Jander O. Singing. In: Sadie S, ed. *The New Grove Dictionary of Music and Musicians.* New York, NY: Grove's Dictionaries of Music; 1980:17.
2. Harris E. The Baroque era voices. In: Brown HM, Sadie S, eds. *Performance Practice: Music After 1600.* New York, NY: WW Norton; 1989.
3. de Bacilly B; Caswell A, trans. 1968. (Originally published as *Remarques curieuses sur l'art de bien chanter.* Paris: 1668.)
4. Witherspoon H. *Singing.* New York, NY: G Schirmer; 1925.
5. Duey P. *Bel Canto in Its Golden Age.* New York, NY: King's Crown Press; 1950.
6. Heriot A. *The Castrati in Opera.* New York, NY: Da Capo Press; 1964.
7. Pleasants H. *The Great Singers.* New York, NY: Simon and Schuster; 1966.

8. Bérnard J-B (J-A). *L'ai-t due Chant*. Paris; 1755.
9. Tosi P-F; Galliard JE, trans. *Observations on the Florid Song*. London; 1742.
10. Mancini G; Buzzi P, trans. *Practical Reflections on the Art of Singing*. Boston, MA: Oliver Ditson; 1907.
11. Coffin B. Vocal pedagogy classics: practical reflections on figured singing by Giambattista Mancini. In: Miller R, ed. *The NATS Bulletin*. 1981;37(4):47–49.
12. Crutchfield W. The 19th century: voices. In: Brown HM, Sadie S, eds. *Performance Practice: Music after 1600*. New York, NY: WW Norton; 1989.
13. Corri D. *The Singer's Preceptor*. London: 1810.
14. García M.P.V.R. *Exercices pour la voix*. Paris: A Parite; c.1820.
15. García M.P.R. *Trait complet de l'art du chant*. Paris: French Academy of Science, 1840.
16. García M.P.R. *Memoire sur la voix humaine*. Paris: E Suverger; 1841.
17. García, M.P.R. *Garcia's Complete School of Singing*. London: Cramer Beal and Chappell; 1872.
18. Klein H. *An Essay on Bel Canto*. London: Oxford University Press; 1923.
19. Lablache L. *Lablache's Complete Method of Singing: or, a Rational Analysis of the Principles According to Which the Studies Should be Directed for Developing the Voice and Rendering it Flexible*. Boston, MA: Oliver Ditson.
20. Lamperti F; Griffith JC, trans. *A Treatise on the Art of Singing*. New York, NY: G Schirmer.
21. Lamperti G-B; Baker T, trans. *The Techniques of Bel Canto*. New York, NY: G. Schirmer; 1905.
22. Brown WE. *Vocal Wisdom: Maxims of Giovanni Battista Lamperti*. New York, NY: Crescendo Press; 1957.
23. Timberlake C. *Apropos of appoggio, parts I and II*. In: McKinney J, ed. *The NATS Journal*. 1995;52(3,4).
24. Stockhausen J. *Method of Singing*. London: Novello; 1884.
25. Seiler E. *The Voice in Singing*. Philadelphia, PA: JB Lippincott; 1875.
26. Behne E. *The Mechanism of the Human Voice*. London: J Curwen & Sons; 1880.
27. Browne L, Behnke E. *Voice Song and Speech*. New York, NY: GP Putnam's Sons; 1897.

28. Delle Sedie E. A Complete Method of Singing. New York: private printing; 1894.
29. Warman EB. The Voice: How to Train It and Care for It. Boston, MA: Lee and Shepard; 1889.
30. Byers MC. Sbriglia's Method of Singing. In: The Etude. May 1942.
31. Marchesi M. Theoretical and Practical Vocal Method. New York, NY: Dover; 1970.
32. Marcesi M. Ten Singing Lessons. New York, NY: Harper & Brothers; 1901.
33. Lehmann L. How to Sing. New York, NY: Macmillan; 1903.
34. Martienssen-Lohmann F. Das bewusste Singen. Leipzig: CF Kahnt; 1923.
35. Martienssen-Lohmann F. Der Opernsänger. Mainz: B Schott's Söhne; 1943.
36. Martienssen-Lohmann F. Der wissende Sänger. Zurich: Atlantis-Verlag; 1963.
37. Armin G. Die Technik der Breitspannung: In: Beitrag über die horizontal-vertikalen Spannkräfte beim Aufbau der Stimme nach dem "Stauprinzip." Berlin: Verlag der Gesellschaft für Stimmkultur; 1932.
38. Armin G. Von der Urkraft der Stimme. Lippstadt: Kistner & Siegel.
39. Husler F. Rodd-Marling Y. Singing: The Physical Nature of the Vocal Organ. London: Faber and Faber; 1960.
40. Johnstone-Douglas W. The teaching of Jean de Reszke, In: Music and Letters; July, 1925.
41. Shakespeare W. The Art of Singing. Bryn Mawr, PA: Oliver Ditson; 1921.
42. Greene HP. Interpretation in Song. London: Macmillan; 1912.
43. White EG. Sinus Tone Production. Boston, MA: Crescendo; 1970.
44. Herbert-Caesari E. The Alchemy of Voice. London: Robert Hale; 1965.
45. Herbert-Caesari E. The Science and Sensations of Tone. Boston, MA: Crescendo; 1968.
46. Herbert-Caesari E. The Voice of the Mind. London: Robert Hale; 1969.
47. Stanley D. The Science of Voice. New York, NY: Carl Fischer; 1929.
48. Reid C. Bel Canto Principles and Practices. New York, NY: Coleman-Ross; 1950.
49. Reid C. Psyche and Soma. New York, NY: J Pattelson Music House; 1975.
50. Reid C. The Free Voice. New York, NY: Coleman-Ross; 1965.

51. Vennard W. *The Mechanism and the Technic*. 5th ed. New York, NY: Carl Fischer; 1967.
52. Coffin B. *Historical Vocal Pedagogy*. Metuchen, NJ: Scarecrow Press; 1989.
53. Coffin B. *Overtones of Bel Canto*. Metuchen, NJ: Scarecrow Press; 1982.
54. Coffin B. *The Sounds of Singing: Vocal Technique with Vowel-Pitch Charts*. Metuchen, NJ: Scarecrow Press; 1977.
55. Appelman R. *The Science of Vocal Pedagogy*. Bloomington, IN: Indiana University Press; 1967.

## فصل ۹

1. Vennard W. *Singing: The Mechanism and Technic*. New York, NY: Carl Fisher; 1949 (2nd ed., 1968).
2. Herbert-Caesari E. *The Voice of the Mind*. New York, NY: Crescendo; 1951.
3. Miller R. *The Structure of Singing: Systems and Art in Vocal Technique*. New York, NY: Schirmer Books; 1984.
4. Stark J. *Bel Canto: A History of Vocal Pedagogy*. Toronto, Canada: University of Toronto Press; 1999.
5. Stewart MA. Effective physician-patient communication and health outcomes: a review. *CMAJ*. 1995;152(9): 1423–1433.
6. Mancia G, Grassi G, Parati G, Zanchetti A. *White Coat Hypertension: An Unresolved Diagnostic and Therapeutic Problem*. Switzerland: Springer International; 2015.
7. Heinrich J. *Voice and the Alexander Technique*. 2nd ed. Berkeley, CA: Mornum Time Press; 2011.
8. Nelson SH, Baldes-Zeller E. *Singing With Your Whole Self: The Feldenkrais Method and Voice*. Lanham, MD: Scarecrow Press; 2001.
9. Lyle H. *Vocal Yoga: The Joy of Breathing, Singing and Sound*. Pacific Palisades, CA: Bluecat Music and Publishing; 2014.
10. Devore K, Cookman S. *The Voice Book*. Chicago, IL: Chicago Review Press; 2009.
11. Titze I. Phonation into a straw as a voice building exercise. *J Singing*. 2000;57(1):27–28.

## فصل ١٠

1. Nair G. *Voice: Traditional and Technology: A State-of-the-Art Studio*. San Diego, CA: Singular Publishing; 1999.

## فصل ١١

1. Sataloff R. *Performing Arts Medicine*. 2nd ed. San Diego, CA: Singular Publishing; 1999.

2. Swan H. *Choral Conducting: A Symposium*. Englewood Cliffs, NJ: Prentice Hall; 1973.

## فصل ١٢

1. Campisi P. The voice of the pediatric laryngologist, treatment and research. *The Voice Foundation Newsletter*. 2005;10(2).

2. Sataloff R. The pediatric larynx and voice: anatomy, development and emerging developments. In: Hartnick CJ, Bosely ME, ed. *Pediatric Voice Disorders*. San Diego, CA: Plural Publishing; 2008:xiii.

3. Dinzans L, Wangerin K, Woodward J. A doctor's dozen: Some observations on voice care of the young performer. *Choral J*. 2006;December:63–71.

4. Bennet P, Bernstorff ED, Flohr J, Fuelberth R, Kerchner J, Trollinger V. *Post-Conference Vocal Health Report. Health Promotion in Schools of Music*. Fort Worth, TX; 2004.

5. Sataloff RT. Arts medicine: an overview for choir conductors. *Choral J*. 2008;49(5):24–33.

6. Blakesee M. National Association for Music Education Position Statement on Musician Health. 2015; <http://www.nafme.org/about/position-statements/health-in-music-education-position-statement/health-in-music-education/>. Accessed August 11, 2015.

7. Reilly JS. The “singing-acting” child: the laryngologist's perspective-1995. *J Voice*. 1995;11(2):126–129.

8. Trollinger V, Justeson J, Kiec, M. Kutztown University Department of Music Master of Education in Music Education degree proposal. Kutztown, PA; 2014.

9. Blakesee M. Personal communication, July 28, 2015.

10. Flohr J, Trollinger V. *Music in Elementary Education*. New York, NY: Pearson; 2010.

11. Phillips K. *Teaching Kids to Sing*. 2nd ed. New York, NY: Schirmer; 2013.
12. Williams J. *Teaching Singing to Children and Young Adults*. Oxford, UK: Compton Publishing; 2013.
13. Trollinger V. Finding your best voice. Texas Music Education Association Annual Convention. San Antonio, TX; February 11–13, 2010.
14. Choksey L. *The Kodaly Method: Comprehensive Music Education from Infant to Adult*. New York, NY: Prentice Hall; 1974.
15. Houlahan M, Tacka P. *Kodaly Today: A Cognitive Approach to Elementary Music Education*. New York, NY: Oxford University Press; 2008.
16. Frazee J, Kreuter K. *Discovering Orff: A Curriculum for Music Teachers*. Mainz, Germany: Schott; 1997.
17. Feierabend J. *First Steps in Music (series)*. Chicago, IL: GIA Publications; 2004.
18. Reynolds A, Bolton B, Taggart C, Gordon E, Valerio W. *Music Play: The Early Childhood Music Curriculum Guide for Parents, Teachers & Caregivers (Jump Right In Preschool)*. 1998.
19. Smith J. Every child a singer: techniques for assisting developing singers. *Music Educators J*. 2006;93(2):28–34.
20. Rutkowski J, Trollinger V. Singing. In: Flohr J, ed. *Music in Early Childhood*. New York, NY: Prentice Hall; 2004: 78–97.
21. Hedden D. An overview of existing research about children’s singing and the implications for teaching children to sing. Update: *Appl Res Music Educ*. 2012;30(2): 52–62.
22. Trollinger VL. The brain in singing and language. *Gen Music Today*. 2010;23(2):20–23.
23. Pfordresher PQ, Demorest SM, Bella SD, et al. Theoretical perspectives on singing accuracy: an introduction to the special issue on singing accuracy (part 1). *Music Percept*. 2015;32(3):227–231.
24. Trollinger VL. Preschool children’s pitch-matching accuracy in relation to participation in Cantoneseimmersion preschools. *J Res Music Educ*. 2004;52(3): 218–233.
25. Trollinger VL. Relationships between Pitch-Matching Accuracy, Speech Fundamental Frequency, Speech Range, Age, and Gender in American English-

- Speaking Preschool Children. MENC: The National Association for Music Education; 2003:78–94.
26. Williams J. *Teaching Singing to Children and Young Adults*. Devon, UK: Compton; 2012.
  27. Welch GF, White P. The developing voice: education and vocal efficiency—a physical perspective. *Bull Council Res Music Educ*. 1993;119:146–156.
  28. Welch GF. The assessment of singing. *Psychol Music*. 1994;22(1):3–19.
  29. Richter B, Nusseck M, Spahn C, Echternach M. Effectiveness of a voice training program for student teachers on vocal health [published online June 6, 2015]. *J Voice*. 2016;30(4):452–459.
  30. Demorest S, Clements A. Factors influencing the pitch-matching of junior high boys. *J Res Music Educ*. 2007;55(3):190–203.
  31. Welch G. Evidence of the development of vocal pitch matching ability in children. *Jpn J Music Educ Res*. 2009; 39(1):38–47.
  32. Demorest SM. Personal Communication, August 13, 2015.
  33. Mang E. The effects of age, gender and language on children’s singing competency. *Br J Music Educ*. 2006; 23(2):161–174.
  34. Trollinger V. Performing arts medicine and music education: what do we really need to know? *Music Educators J*. 2005;92(2):42–48.
  35. Trollinger V. Technology for musicians: review of the singing coach and singing coach Kidz Software. *Gen Music Today*. 2007;20(2):39–41.
  36. Bowers J, Daugherty JE. Self-reported student vocal use at a high school summer choral camp. *Int J Res Choral Singing*. 2008;3(1):39–44.
  37. Daugherty JF, Manternach JN, Price KK. Student voice use and vocal health during an All-State Chorus Event. *J Res Music Educ*. 2011;58(4):346–367.
  38. Price HE, Yarbrough C, Jones M, Moore RS. Effects of male timbre, falsetto, and sine-wave models on interval matching by inaccurate singers. *J Res Music Educ*. 1994;42(4):269.
  39. Yarbrough C, Bowers J, Benson W. The Effect of Vibrato on the Pitch-Matching Accuracy of Certain and Uncertain Singers. *Music Educators National Conference*; 1992:30.
  40. Green GA. The effect of vocal modeling on pitchmatching accuracy of elementary schoolchildren. *J Res Music Educ*. 1990;38(3):225–231.

41. Duvvuru S, Erickson M. The effect of timbre, pitch, and vibrato on vocal pitch-matching accuracy [published online June 17, 2015]. *J Voice*. 2016;30(3):378.e12.
42. Watts CR, Hall MD. Timbral influences on vocal pitchmatching accuracy. *Logop Phoniatr Vocol*. 2008;33(2): 74–82.
43. Granot RY, Israel-Kolatt R, Gilboa A, Kolatt T. Accuracy of pitch matching significantly improved by live voice model. *J Voice*. 27(3):390.e13390.e2044.
44. Trollinger V, White C. Facial expressions affect on pitchmatching accuracy in children. Florida Music Educators Association Annual Conference. Tampa, FL; January 11, 2013.
45. Pascale LM. Dispelling the myth of the non-singer: embracing two aesthetics for singing. *Phil Music Educ Rev*. 2005;13(2):165–175.
46. Sergeant D, Sjölander P, Welch G. Listener’s identifications of gender differences in children’s singing. *Res Studies Music Educ*. 2005;24:28–39.
47. Shehan-Campbell P, Scott-Kassner C. *Music in Childhood: From Preschool Through the Elementary Grades*. 4th ed. Boston, MA: Cengage Learning; 2012.
48. Trollinger V. Pediatric vocal development and voice science: implications for teaching singing. *Gen Music Today*. 2007;20(3):19–25.
49. Williams J. A female teacher’s perspective of teaching males in middle and high school chorus. *Choral J*. 2012; 52(10):18–27.
50. Persellin DC. The effects of vocal modeling, musical aptitude, and home environment on pitch accuracy of young children. *Bull Council Res Music Educ*. 2006;169: 39–50.
51. Custodero LA. Singing practices in 10 families with young children. *J Res Music Educ*. 2006;54(1):37–56.
52. Andrews ML, Summers AC. *Voice Treatment for Children and Adolescents*. Clifton Park, NY: Delmar/Cengage Learning; 2001.
53. Trollinger V. World vocal traditions and vocal health: is a reconciliation possible? International Society of Music Education 27th World Conference. Kuala Lumpur, Malaysia; July 13, 2006.
54. Greathouse P. *Mariachi*. Layton, UT: Smith, Gibbs Publisher; 2009.
55. Lopez J. Mastering Mariachi. *Southwestern Music Educ*. 2011(September):32–34.



56. Pullman P. The big question. *Intelligent Life*; 2015. <http://moreintelligentlife.com/node/6939>. Accessed September 9, 2015.
57. Gordon E. *Gordon Music Learning Theory*; 2015. <http://giml.org/mlt/>. Accessed September 9, 2015.
58. Demorest SM. *Building Choral Excellence: Teaching SightSinging in the Choral Rehearsal*. New York, NY: Oxford University Press; 2013.
59. Little Kids Rock. <http://www.littlekidsrock.org/>. Accessed September 15, 2015.
60. American Academy of Teachers of Singing. *Position Statement on Teaching Children to Sing*; 2002. <http://www.americanacademyofteachersofsinging.org/assets/articles/TeachingChildren.pdf>. Accessed August 13, 2015.
61. Wurgler PS. *A Perceptual Study of Vocal Registers in the Singing Voices of Children*. Columbus, OH: Ohio State University; 1990.
62. Demorest SM, Pfordresher PQ, Bella SD, et al. Methodological perspectives on singing accuracy: an introduction to the special issue on singing accuracy (part 2). *Music Percept*. 2015;32(3):266–271.
63. Wassum S. Elementary school children's vocal range. *J Res Music Educ*. 1979;27:214–226.
64. McAllister AM, Granqvist S, Sjölander P, Sundberg J. Child voice and noise: a pilot study of noise in day cares and the effects on 10 children's voice quality according to perceptual evaluation. *J Voice*. 2009;23(5):587–593.
65. Thurman L, Welch G, Theimer A, Klitzke C. Addressing vocal register discrepancies: an alternative, sciencebased theory of register phenomena. *Second International Conference on the Physiology and Acoustics of Singing*. National Center for Voice and Speech, Denver, CO; October 6–9, 2004.
66. Runfola M, Rutkowski J. *TIPS: The Child Voice*. Lanham, MD: Rowman & Littlefield Education; 2010.
67. Phillips K. *Directing the Choral Music Program*. 2nd ed. New York, NY: Oxford University Press; 2015.
68. Smith B, Sataloff R. *Choral Pedagogy*. 3rd ed. San Diego, CA: Plural Publishing; 2013.
69. Williams J. *The Implications of Intensive Singing Training on the Vocal Health and Development of Boy Choristers in an English Cathedral Choir*. Institute of Education, University of London; 2010.

70. Jentschke S, Koelsch S. Musical training modulates the development of syntax processing in children. *Neuroimage*. 2009;47:735–744.
71. Nix J. “You want me to do what?”: twenty-first-century voice pedagogy encounters pedagogical fundamentalism. *Choral J*. 2013;53(10):43–51.
72. Bourne T, Kenny D. Vocal qualities in music theater voice: perceptions of expert pedagogues [published online April 14, 2015]. *J Voice*. 2016;30(1):128.e1–12.
73. McPherson GE, Welch GF, Phillips KH, Williams J, Edwin R. The young singer. In: *The Oxford Handbook of Music Education*. London: Oxford University Press; 2012:594–609.
74. Arboleda BW. Strength training and rock singing for the young. *J Singing*. 2013;69(4):463–465.
75. Donahue EN, LeBorgne WD, Brehm SB, Weinrich BD. Reported vocal habits of first-year undergraduatemusical theater majors in a preprofessional training program: a 10-year retrospective study. *J Voice*. 2014; 28(3):316–323.
76. Edwin R. Popular song and music theater. Repertoire for child singers. *J Singing*. 2012;68(4):443–444.
77. Sataloff R. Professional singers: the science and art of clinical care. *Am J Otolaryngol*. 1981;2(3):251–266.
78. LaPine PR. The relationship between the physical aspects of voice production and optimal vocal health. *Music Educ J*. 2008;94(3):24–29.

### فصل ۱۳

1. Voice and Speech Trainers Association (VASTA). Typical Job Responsibilities. Accessed March 3, 2015. [http:// www.vasta.org/promotion-tenure-hiring-resources](http://www.vasta.org/promotion-tenure-hiring-resources).
2. Raphael BN. A consumer’s guide to voice and speech training. *N Engl Theatre J*. 1994;5:101–114.
3. Skinner E, Mansell L, ed. *Speak with Distinction*. New York, NY: Applause Theatre Book Publishers; 1990.
4. Linklater K. *Freeing the Natural Voice*. New York, NY: Drama Publishers; 1976.
5. Linklater K. *Freeing Shakespeare’s Voice*. New York, NY: Theatre Communications Group; 1992.
6. Lessac A. *The Use and Training of the Human Voice: A Practical Approach to Speech and Voice Dynamics*. New York, NY: Drama Publishers; 1967

7. Lessac A. *Body Wisdom: The Use and Training of the Human Body*. Claremont, CA: Arthur Lessac; 1978.
8. Berry C. *Voice and the Actor*. London: Harrap; 1973.
9. Berry C. *The Actor and His Text*. London: Harrap; 1987.
10. Turner JC. *Voice and Speech in the Theatre*. 3rd ed. London: Pitman; 1977.
11. Rodenburg P. *The Right to Speak*. London: Methuen Drama; 1992.
12. Rodenburg P. *The Need for Words*. London: Methuen Drama; 1993.
13. Saklad, N. *Voice and Speech Training in the New Millennium: Conversations With Master Teachers*. Milwaukee, WI: Applause Theatre & Cinema Books; 2011.
14. Alexander FM, McGowen D, eds. *Alexander Technique: Original Writings of FM Alexander: Constructive Conscious Control*. New York, NY: Larson Publications; 1997.
15. Feldenkrais M. *Awareness Through Movement: Easy to Do Health Exercises to Improve Posture, Vision, Imagination and Personal Awareness*. San Francisco, CA: HarperOne; 2009.
16. Pilates J. *Return to Life*. North Bay Village, FL: Pilates Method Alliance, Inc; 2012.
17. Silva M, Mehta S. *Yoga The Iyengar Way*. New York, NY: Alfred A. Knopf; 1990.
18. Voice and Speech Trainers Association (VASTA). *VASTA Links*. Accessed March 3, 2015. <http://www.vasta.org/vasta-links>.
19. The Voice Foundation. *Annual Symposium: Care of the Professional Voice*. <http://www.voicefoundation.org/events/annual-symposium/>.

## فصل ١٤

1. Mathieson L. Vocal tract discomfort in hyperfunctional dysphonia. *Voice*. 1993;2:40–48.
2. Mathieson L. *Greene and Mathieson's The Voice and Its Disorders*. 6th ed. London, England: Whurr Publishers; 2001.
3. Roy N, Leeper HA. Effects of the manual laryngeal musculoskeletal tension reduction technique as a treatment for functional voice disorders: perceptual and acoustic measures. *J Voice*. 1993;7:242–249.

4. Roy N, Bless DM, Heisey D, Ford CN. Manual circumlaryngeal therapy for functional dysphonia: an evaluation of short- and long-term treatment outcomes. *J Voice*. 1997;11:321–331.
5. Aronson AE. *Clinical Voice Disorders: An Interdisciplinary Approach*. 2nd ed. New York, NY: Georg Thieme Verlag; 1985.
6. Aronson A. *Clinical Voice Disorders*. 3rd ed. New York, NY: Thieme Medical Publishers; 1991:117–145.
7. Harris S, Harris T, Lieberman J, Harris D. The multidisciplinary voice clinic. In: Freeman M, Fawcus M, eds. *Voice Disorders and Their Management*. London, England: Whurr Publishers; 2000:313–332.
8. Harris T. Laryngeal mechanisms in normal function and dysfunction. In: Harris T, Harris S, Rubin JS, Howard DM, eds. *The Voice Clinic Handbook*. London, England: Whurr Publishers; 1998:64–90.
9. Rubin JS. The structural anatomy of the larynx and supraglottic vocal tract: a review. In: Harris T, Harris S, Rubin JS, Howard DM, eds. *The Voice Clinic Handbook*. London, England: Whurr Publishers; 1998:15–33.
10. Laitman JT, Noden DM, Van de Water TR. Formation of the larynx: from homeobox genes to critical periods. In: Rubin JS, Sataloff RT, Korovin GS, Gould WJ, eds. *Diagnosis and Treatment of Voice Disorders*. New York, NY: Igaku-Shoin Medical Publishers; 1995:9–23.
11. Scherer RC. Laryngeal function during phonation. In: Rubin JS, Sataloff RT, Korovin G, Gould WJ, eds. *Diagnosis and Treatment of Voice Disorders*. New York, NY: Igaku-Shoin Publishers; 1995:86–104.
12. Hast MH. Mechanical properties of the cricothyroid muscle. *Laryngoscope*. 1966;76:537–548.
13. Cooper DS, Partridge LD, Alipour-Haghighi F. Muscle energetics, vocal efficiency, and laryngeal biomechanics. In: Titze IR, ed. *Vocal Fold Physiology: Frontiers in Basic Science*. San Diego, CA: Singular Publishing Group; 1993:37–92.
14. Harris T, Lieberman J. The cricothyroid mechanism, its relationship to vocal fatigue and vocal dysfunction. *Voice*. 1993;2:89–96.
15. Rubin JS, Sataloff RT. *Voice: new horizons*. In: Sataloff RT, ed. *Professional Voice: The Science and Art of Clinical Care*. 2nd ed. San Diego, CA: Singular Publishing Group; 1997.

16. Fisher K. Early experience of a multidisciplinary pain management programme. *Hol Med.* 1988;3:47–56.
17. Robinson L, Fisher H, Knox J, Thomson G. *The Official Body Control Pilates Manual.* London, England: Macmillan Publishers; 2000.
18. Feldenkrais M. *Awareness Through Movement.* New York, NY: Harper & Row; 1972.
19. Rolf IP. *Rolfing: Reestablishing the Natural Alignment and Structural Integration of the Human Body for Vitality and Well-Being.* Rochester, VT: Healing Arts Press; 1989.
20. Dickson D, Dickson W. Functional anatomy of the human larynx. *Trans Pa Acad Ophthalmol Otolaryngol.* 1972;25(1):29–38.
21. Boileau Grant JC. *Grant's Atlas of Anatomy.* 6th ed. Baltimore, MD: Williams & Wilkins; 1972.
22. Lieberman J. Principles and techniques of manual therapy: application in the management of dysphonia. In: Harris T, Harris S, Rubin JS, Howard DM, eds. *The Voice Clinical Handbook.* London, England: Whurr Publishers; 1998:91–138.
23. Dickson DR, Maue-Dickson W. *Anatomical and Physiological Basis of Speech.* Boston, MA: Little, Brown & Co; 1982.
24. Takano S, Honda K, Kinoshita K. Measurement of cricothyroid articulation using high-resolution MRI and 3D pattern matching. *Acta Acust united Ac.* 2006;92(5): 725–730.
25. Letson JA Jr, Tatchell R. Arytenoid movement. In: Sataloff RT, ed. *Professional Voice: The Science and Art of Clinical Care.* San Diego, CA: Singular Publishing Group; 1997:131–145.
26. Baken RJ, Isshiki N. Arytenoid displacement by simulated intrinsic muscle contraction. *Folia Phoniatr.* 1977; 29:206–216.
27. von Leden H. The mechanics of the cricoarytenoid joint. *Arch Otolaryngol.* 1961;73:63–72.
28. Arnold GE. Physiology and pathology of the cricothyroid muscle. *Laryngoscope.* 1961;71:687–753.
29. Choi HS, Berke GS, Ye M, Kreiman J. Function of the thyroarytenoid muscle in a canine laryngeal model. *Ann Otol Rhinol Laryngol.* 1993;102:769–776.

30. Fujimura O. Body-cover theory of the vocal fold and its phonetic implications. In: Stevens KN, Hirano M, eds. *Vocal Fold Physiology*. Tokyo, Japan: University of Tokyo Press; 1981:271–288.
31. Titze IR, Jiang J, Drucker DG. Preliminaries to the bodycover theory of pitch control. *J Voice*. 1988;1(4):314–319.
32. Vilkman E, Alku P, Laukkanen A. Vocal-fold collision mass as a differentiator between registers in the lowpitch range. *J Voice*. 1995;9:66–73.
33. Alipour-Haghighi F, Perlman AL, Titze IR. Tetanic response of the cricothyroid muscle. *Ann Otol Rhinol Laryngol*. 1991;100:626–631.
34. Alipour-Haghighi F, Titze IR, Perlman AL. Tetanic contraction in vocal fold muscle. *J Speech Hear Res*. 1989;32: 226–231.
35. Titze IR, Durham PL. Passive mechanisms influencing fundamental frequency control. In: Baer T, Sasaki C, Harris KS, eds. *Laryngeal Function in Phonation and Respiration*. San Diego, CA: College-Hill Press; 1987: 304–319.
36. Broniatowski M, Sonies BC, Rubin JS, et al. Current evaluation and treatment of patients with swallowing disorders. *Otolaryngol Head Neck Surg*. 1999;120:464–473.
37. Hellemans J, Agg HO, Pelemans W, et al. Pharyngoesophageal swallowing disorders and the pharyngoesophageal sphincter. *Med Clin North Am*. 1981;65:1149–1171.
38. Estill J. *Voicecraft: A User’s Guide to Voice Quality*. Vol 2, *Some Basic Voice Qualities*. Santa Rosa, CA: Estill Voice Training Systems; 1995.
39. Rubin JS. The physiologic anatomy of swallowing. In: Rubin JS, Broniatowski M, Kelly J, eds. *The Swallowing Handbook*. San Diego, CA: Singular Publishing Group; 2000:1–20.
40. Sonninen A. The role of the external laryngeal muscles in the length-adjustment of the vocal cords in singing. *Acta Otolaryngol*. 1956;118:218–231.
41. Vilkman E, Sonninen A, Hurme P, Korkko P. External laryngeal frame function in voice production revisited: a review. *J Voice*. 1996;10:78–92.
42. Lumley JSP, Craven JL, Aitken JT. *Essential Anatomy*. Edinburgh, Scotland: Churchill Livingstone; 1973.
43. Rubin JS, Lieberman J, Harris TM. Laryngeal manipulation. *Otolaryngol Clin North Am*. 2000;33:1017–1034.

44. Rubin JS. Mechanisms of respiration (the bellows). In: Harris T, Harris S, Rubin JS, Howard DM, eds. *The Voice Clinic Handbook*. London, England: Whurr Publishers; 1998:49–63.
45. Morrison MD, Rammage LA, Gilles M, et al. Muscular tension dysphonia. *J Otolaryngol*. 1983;12:302–306.
46. Morrison M, Rammage L, Nichol H, et al. *The Management of Voice Disorders*. San Diego, CA: Singular Publishing Group; 1994.
47. Harris S. Speech therapy for dysphonia. In: Harris T, Harris S, Rubin JS, Howard DM, eds. *The Voice Clinic Handbook*. London, England: Whurr Publishers; 1998:186–195.
48. Gould WJ, Rubin JS. Special considerations for the professional voice user. In: Rubin JS, Sataloff RT, Korovin G, Gould WJ, eds. *Diagnosis and Treatment of Voice Disorders*. New York, NY: Igako-Shoin Press; 1995: 424–435.
49. Koufman J, Blalock O. Functional voice disorders. *Otolaryngol Clin North Am*. 1991;24:1059–1073.

## فصل ١٥

1. Morrison M, Rammage L. Muscle misuse voice disorders: description and classification. *Acta Otolaryngol*. 1993;113:428–434.
2. Fisher K. Early experience of a multidisciplinary pain management programme. *Holistic Med*. 1988;3:7–56.
3. Robinson L, Fisher H, Knox J, Thomson. *The Official Body Control Pilates Manual*. London, England: Macmillan Publishers; 2000.
4. Feldenkrais M. *Awareness Through Movement*. New York, NY: Harper and Row; 1972.
5. Franco I. The sagittal postural alignment different in normal and dysphonic adult speakers? *J Voice*. 2014;28: 523.
6. Ogawa M, Yoshida M, Watanabe K, et al. Association between laryngeal findings and vocal qualities in muscle tension dysphonia with supraglottic contraction [in Japanese]. *Nihon Jibiinkoka Gakkai Kaiho*. 2005; 108:734–741.
7. Roy N, Ford C, Bless D. Muscle tension dysphonia and spasmodic dysphonia: the role of manual laryngeal tension reduction in diagnosis and management. *Ann Otol Rhinol Laryngol*. 1996;105:851–856.

8. Van Houtte E, Van Lierde K, Clayes S. Pathophysiology and treatment of muscle tension dysphonia: a review of the current knowledge. *J Voice*. 2011;25:202–207.
9. Teive H. Essential tremor: phenotypes. *Parkinsonism Relat Disord*. 2012;18:140.
10. Rolf IP. *Rolfing: Reestablishing the Natural Alignment and Structural Integration of the Human Body for Vitality and Well-being*. Rochester, VT: Healing Arts Press; 1989.
11. Devreese A, Staes F, Janssens L, et al. Incontinent women have altered pelvic floor muscle contraction patterns. *J Urol*. 2007;178:558–564.
12. Lumley JSP, Craven JL, Aitken JT. *Essential Anatomy*. Edinburgh, Scotland: Churchill Livingstone; 1973.
13. Ger R, Abrahams P, Olson TR. *Essentials of Clinical Anatomy*. 2nd ed. New York, NY: Parthenon Publishing Group; 1996.
14. *Stedman's Medical Dictionary*. 22nd ed. Baltimore, MD: Williams and Wilkins; 1972.
15. Boileu Grant JC, Basmajian JV. *Grant's Method of Anatomy*. 7th ed. Baltimore, MD: Williams and Wilkins; 1965.
16. Kooijman PG, de Jong FI, Oudes MJ, et al. Muscular tension and body posture in relation to voice handicap and voice quality in teachers with persistent voice complaints. *Folia Phoniatr*. 2005;57:134.
17. Iwarsson J. Effects of inhalatory abdominal wall movement on vertical laryngeal position during phonation. *J Voice*. 2001;15:384–394.
18. Rubin JS, Korovin G, Epstein R. Care for the professional voice. In: Rubin JS, Sataloff RT, Korovin G, eds. *Diagnosis and Treatment of Voice Disorders*. 2nd ed. Clifton Park, NY: Thomas Delmar Learning; 2003.
19. Miller NA, Gregory JS, Semple SI, et al. Relationships between vocal structures, the airway and cranio-cervical posture investigated using magnetic resonance imaging. *J Voice*. 2012;26:102–109.
20. Miller N, Gregory J, Aspden R, Stolley P, Gilbert F. Using active shape modeling based on MRI to study morphologic and pitch related functional changes affecting vocal structures and the airway. *J Voice*. 2014; 28:554–564.
21. Moradi N, Maroufi N, Bijankhan M, et al. Intrarater and interrater reliability of sagittal head posture: a novel technique performed by a physiotherapist and a speech and language pathologists. *J Voice*. 2014;28:842. e11–e16.



22. Vintturi J, Alku P, Lauri ER, et al. The effects of postloading rest on acoustic parameters with special reference to gender and ergonomic factors. *Folia Phoniatr*. 2001;53:338–350.
23. Vilkman E. Occupational safety and health aspects of voice and speech profession. *Folia Phoniatr Logop*. 2004;56:220–253.
24. Lieberman J. Principles and techniques of manual therapy. In: Harris T, Harris S, Rubin JS, Howard D, eds. *The Voice Clinic Handbook*. London, England: Whurr Publishers; 1998:91–138.
25. Koufman J, Blalock O. Functional voice disorders. *Otolaryngol Clin North Am*. 1991;24:1059–1073.
26. Rubin JS, Lieberman J, Harris TM. Laryngeal manipulation. *Otolaryngol Clin North Am*. 2000;33:1017–1034.
27. Aronson A. *Clinical Voice Disorders*. 3rd ed. New York, NY: Thieme Medical Publishers; 1991:117–145.
28. de Gelder B, de Borst A, Watson R. The perception of emotion in body expression. *Wiley Interdiscip Rev Cogn Sci*. 2015;6:149–158.
29. Brinol P, Petty R, Wagner B. Body posture effects on self-evaluation: a self-validation approach. *Eur J Soc Psychol*. 2014;39:1053–1064.
30. Giovanni A, Assaiante C, Galmiche A, et al. Vocal forcing and posture: experimental studies on normal subjects. *Rev Laryngol Otol Rhinol (Bord)*. 2006;127:285–291.
31. Lagier A, Vaugoyeau M, Ghio A, et al. Coordination between posture and phonation in vocal effort behaviour. *Folia Phoniatr*. 2010;62:195–202.
32. Johnson G, Skinner, M. The demands of professional opera singing on cranio-cervical posture. *Eur Spine J*. 2009;18:562–569.
33. Mathieson L. *Greene and Mathieson's The Voice and Its Disorders*. 6th ed. London, England: Whurr Publishers Ltd; 2001.
34. Mathieson L, Hirani, SP, Epstein R, Baken RJ, Wood G, Rubin JS. Laryngeal Manual Therapy: A preliminary study to examine its treatment effects in the management of muscle tension dysphonia. *J Voice*. 2009;23:353–366.
35. Mathieson L. The evidence for laryngeal manual therapies in the treatment of muscle tension dysphonia. *Curr Opin Otolaryngol Head Neck Surg*. 2011;19:171–176.

36. Roy N, Leeper HA. Effects of the manual laryngeal musculoskeletal tension reduction technique as a treatment for functional voice disorders: perceptual and acoustic measures. *J Voice*. 1993;7:242–249.
37. Staes F, Jansen L, Vilette A, et al. Physical therapy as a means to optimize posture and voice parameters in student classical singers: a case report. *J Voice*. 2011;25: e91–e101.
38. Nacci A, Fattori B, Mancini V, et al. Posturographic analysis in patients with dysfunctional dysphonia before and after speech therapy/rehabilitation treatment. *Acta Otolaryngol*. 2012;32:115–121.
39. Bruno E, De Padova A, Napolitano B, et al. Voice disorders and posturography: variables to define the success of rehabilitative treatment. *J Voice*. 2009;23:71–75.
40. Dromey C, Nissen S, Roy N, Merrill R. Articulatory changes following treatment of muscle tension dysphonia: preliminary acoustic evidence. *J Speech Lang Hear Res*. 2008;51:196–208.

## فصل ۱۶

1. Council on Foods and Nutrition. Nutrition teaching in medical schools. *JAMA*. 1963;183(11):955–957.
2. Mahan LK, Escott-Stump S, Raymond JL. Krause's Food and the Nutrition Care Process. St Louis, MO: Elsevier Health Sciences; 2012.
3. Subcommittee on the Tenth Edition of the RDAs, Food and Nutrition Board, Commission on Life Sciences, National Research Council. Dietary Recommended Allowances. 10th ed. Washington, DC: National Academy Press; 1989.
4. Otten JJ, Hellwig JP, Meyers LD. Dietary Reference Intakes: the Essential Guide to Nutrient Requirements. National Academies Press; 2006. <https://fnic.nal.usda.gov/dietary-guidance/dietary-reference-intakes/dri-nutrient-reports>
5. Tagtow A, Haven J, Maniscalco S, Bailey DJ, Bard S. MyPlate celebrates 4 years. *J Acad Nutr Diet*. 2015; 115(7):1039–1040.
6. US Department of Agriculture, Choose MyPlate. MyPlate. 2016. <http://www.choosemyplate.gov/MyPlate>
7. Center for Nutrition Policy and Promotion. A Brief History of USDA Food Guides; 2011. <http://www.choosemyplate.gov>
8. US Senate Select Committee on Nutrition and Human Needs. Dietary Goals for the United States. 2nd ed. Washington, DC: US Government Printing Office; 1977.

9. Dietary Guidelines for Americans 2015–2020. Washington, DC: US Department of Agriculture (USDA), Human Nutrition Information Service; 2015.
10. Ratner RE and Diabetes Prevention Program Research. An update on the Diabetes Prevention Program. *Endocr Pract.* 2006;12(suppl 1):20–24.
11. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med.* 2002; 346(6):393–403.
12. Dutton GR, Lewis CE. The Look AHEAD Trial: implications for lifestyle intervention in type 2 diabetes mellitus. *Prog Cardiovasc Dis.* 2015;58(1):69–75.
13. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention. 2011 Jan;201(1).
14. Hamdan AL, Jabbour J, Nassar J, Dahouk I, Azar ST. Vocal characteristics in patients with type 2 diabetes mellitus. *Eur Arch Otorhinolaryngol.* 2012;269(5):1489–1495.
15. Schechter GL, Kostianovsky M. Vocal cord paralysis in diabetes mellitus. *Trans Am Acad Ophthalmol Otolaryngol.* 1972;76(3):729–740.
16. American Diabetes Association. [www.diabetes.org](http://www.diabetes.org).
17. Position Statement of the American Diabetes Association: Nutrition recommendations and interventions for diabetes. *Diabetes Care.* 2008;31(suppl 1):S61–S78.
18. Pories WJ, Caro JF, Flickinger EG, Meelheim HD, Swanson MS. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass. *Ann Surg.* 1987;206(3):316–323.
19. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. *Ann Surg.* 1995;222(3):339–350; discussion 350–352.
20. Long SD, O'Brien K, MacDonald KG Jr, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. *Diabetes Care.* 1994;17(5):372–375.

21. Laferrère B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. *J Clin Endocrinol Metab.* 2008;93(7):2479–2485.
22. Hamdan AL, Safadi B, Chamseddine G, et al. Effect of weight loss on voice after bariatric surgery. *J Voice.* 2014;28(5):618–623.
23. Hawkshaw MJ, Pebdani P, Sataloff RT. Reflux laryngitis: an update, 2009-2012. *J Voice.* 2013;27(4):486–494.
24. Ross JA, Noordzji JP, Woo P. Voice disorders in patients with suspected laryngopharyngeal reflux disease. *J Voice.* 1998;12(1):84–88.
25. Nelms M. Diseases of the upper gastrointestinal tract. In: Nelms M, Sucher KP, Long S, eds. *Nutrition Therapy and Pathophysiology.* Belmont, CA: Thomson Brooks/ Cole; 2007:433–436.
26. Gaynor EB. Otolaryngologic manifestations of gastroesophageal reflux. *Am J Gastroenterol.* 1991;86(7): 801–808.
27. Esmailzadeh A, Keshteli AH, Feizi A, et al. Patterns of diet-related practices and prevalence of gastro-esophageal reflux disease. *Neurogastroenterol Motil.* 2013; 25(10):831–838.
28. Randhawa MA, Mahfouz SA, Selim NA, Yar T, Gillessen A. An old dietary regimen as a new lifestyle change for gastroesophageal reflux disease: a pilot study. *Pak J Pharm Sci.* 2015;28(5):1583–1586.
29. Johns Hopkins Voice Center. [www.gbmc.org/reflux\\_changestothelarynx](http://www.gbmc.org/reflux_changestothelarynx).
30. Thomas DT, Erdman KA, Burke LM. Position of the Academy of Nutrition and Dietetics, Dietitians of Canada, and the American College of Sports Medicine: Nutrition and Athletic Performance. *J Acad Nutr Diet.* 2016;116(3):501–528.
31. Trexler ET, Smith-Ryan AE, Norton LE. Metabolic adaptation to weight loss: implications for the athlete. *J Int Soc Sports Nutr.* 2014;11(1):1.
32. Roberts SB, Dallal GE. Energy requirements and aging. *Public Health Nutr.* 2005;8(7A):1028–1036.
33. Poehlman ET, Goran M, Gardner A, et al. Determinants of decline in resting metabolic rate in aging females. *Am J Physiol Endocrinol Metab.* 1993; 264:E450–E455.
34. Poehlman ET. Energy expenditure and requirements in aging humans. *J Nutr.* 1992;122:2057–2065.

35. Harris J, Benedict F. A Biometric Study of Basal Metabolism in Man. Philadelphia, PA: Lippencott; 1919.
36. Mifflin MD, St Jeor ST, Hill LA, et al. A new predictive equation for resting energy expenditure in healthy individuals. *Am J Clin Nutr.* 1990;51(2):241–247.
37. Institute of Medicine. Food and Nutrition Board. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients). Washington, DC: The National Academies Press; 2005.
38. Berning JR, Steen SN. Nutrition for Sport and Exercise. 2nd ed. Gaithersburg, MD: Aspen Publishers; 1998.
39. van Wyk L, Cloete M, Hattingh D, et al. The effect of hydration on the voice quality of future professional vocal performers [published online February 9, 2016]. *J Voice.* doi:10.1016/j.jvoice.2016.01.002
40. Dick RW, Berning JR, Dawson W, et al. Athletes and the arts—the role of sports medicine in the performing arts. *Curr Sports Med Rep.* 2013;12(6):397–403.
41. Reilly T, Waterhouse J, Burke LM, et al. Nutrition for travel. *J Sports Sci.* 2007;25(suppl 1):S125–S134.
42. Centers for Disease Control and Prevention. Handwashing: clean hands save lives. Atlanta, GA: US Department of Health and Human Services; 2016. <http://www.cdc.gov/handwashing/why-handwashing.html>
43. Ranchordas MK, Rogerson D, Ruddock A, Killer SC, Winter EM. Nutrition for tennis: practical recommendations. *J Sports Sci Med.* 2013;12(2):211–224.

## فصل ١٧

1. Sataloff RT, Lawrence VL, Hawkshaw M, Rosen DC. Medications and their effects on the voice. In: Benninger MS, Jacobson BH, Johnson AF, eds. *Vocal Arts Medicine: The Care and Prevention of Professional Voice Disorders.* New York, NY: Thieme Medical Publishers; 1994:216–225.
2. Lawrence VL. Common medications with laryngeal effects. *Ear Nose Throat J.* 1987;66(8):318–322.
3. Schiff M. Medical management of acute laryngitis. In: Lawrence VL, ed. *Transcripts of the Sixth Symposium: Care of the Professional Voice.* New York, NY: The Voice Foundation; 1977:99–102.

4. Schiff M. Comment at the Seventh Symposium: Care of the Professional Voice. New York, NY: The Juilliard School; 1978.
5. Punt NA. Vocal disabilities of singers. Applied laryngology—singers and actors. Proc R Soc Med. 1968;61: 1152–1156.
6. Williams AJ, Baghat MS, Stableforth DE, et al. Dysphonia caused by inhaled steroids: recognition of a characteristic laryngeal abnormality. Thorax. 1983;38: 813–821.
7. Watkin KL, Ewanowski SJ. Effects of aerosol corticosteroids on the voice: triamcinolone acetonide and beclomethasone dipropionate. J Speech Hear Res. 1985; 28:301–304.
8. Toogood JH, Jennings B, Greenway RW, Chuang L. Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J Allergy Clin Immunol. 1980; 65(2):145–153.
9. Davies WL, Grunert RR, Haff RF, et al. Antiviral activity of 1-amantanamine (amantadine). Science. 1964; 144:862–863.
10. McGahen JW, Hoffman CE. Influenza infections of mice. Curative activity of amantadine HCl. Proc Soc Exp Biol Med. 1968;129:678–681.
11. Wingfield WL, Pollack D, Grunert RR. Therapeutic efficacy of amantadine-HCl and rimantidine-HCl in naturally occurring influenza A2 respiratory illness in man. N Engl J Med. 1969;281:579–584.
12. Council on Drugs. The amantadine controversy. JAMA. 1967;201:372–373.
13. Martin FG. Drugs and vocal function. J Voice. 1988;2(4): 338–344.
14. Nursing '89 Drug Handbook. Springhouse, PA: Springhouse Corporation; 1989:236.
15. Gates GA, Saegert J, Wilson N, et al. Effect of betablockade on singing performance. Ann Otol Rhinol Laryngol. 1985;94:570–574.
16. Rasmussen L, Oster-Jorgensen E, Qvist N, et al. Short report: a double-blind placebo-controlled trial of omeprazole on characteristics of gastric emptying in healthy subjects. Aliment Pharmacol Ther. 1991;5:85–89.
17. Bough ID Jr, Sataloff RT, Castell DO, et al. Gastroesophageal reflux laryngitis resistant to omeprazole therapy. J Voice. 1995;9(2):205–211.

18. Lawrence VL. Medical care for professional voice. [Panel.] In: Lawrence VL, ed. *Transcripts from the Annual Symposium: Care of the Professional Voice*. New York, NY: The Voice Foundation; 1978:3:17–18.
19. Damsté PH. Changes in the voice caused by drugs. In: Meyer L, Pach HM, eds. *Drug Induced Diseases*. Amsterdam, The Netherlands: Excerpta Medica; 1978:543–548.
20. Damsté PH. [Virilization of the voice due to anabolic steroids.] *Ned Tijdschr Geneeskd*. 1963;107:891–892.
21. Damsté PH. Voice change in adult women caused by virilizing agents. *J Speech Hear Disord*. 1967;32:126–132.
22. Derman RJ. Effects of sex steroids on women's health: implication for practitioners. *Am J Med*. 1995;98(1A): 137S–143S.
23. Pinsky L, Kaufman M, Killinger DW. Impaired spermatogenesis is not an obligate expression of receptor defective androgen resistance. *Am J Med Genet*. 1989; 32(1):100–104.
24. Rolf C, Nieschlag E. Potential adverse effects on longterm testosterone therapy. *Baillieres Clin Endocrinol Metab*. 1998;12(3):521–534.
25. Pedersen MF, Moller S, Krabbe S, et al. Fundamental voice frequency in female puberty measured with electroglottography during continuous speech as a secondary sex characteristic. A comparison between voice, pubertal stages, oestrogens and androgens. *Int J Pediatr Otorhinolaryngol*. 1990;20(1):17–24.
26. Saez S, Francoise S. Recepteurs d'androgenes: mise en evidence dans la fraction cytosolique de muqueuse normale et d'epitheliomas pharyngolarynges humains. *CR Acad Sci (Paris)*. 1975;280:935–938.
27. Vuorenkoski V, Lenko HL, Tjernlund P, et al. Fundamental voice frequency during normal and abnormal growth, and after androgen treatment. *Arch Dis Child*. 1978;53:201–209.
28. Arndt HJ. Stimmstörungen nach Behandlung mit androgenen und anabolen hormonen. *Munch Med Wochenschr*. 1974;116:1715–1720.
29. Bourdial J. Les troubles de la voix provoques par la therapeutique hormonale androgene. *Ann Otolaryngol Chir Cervicofac*. 1970;87:725–734.
30. Joura EA, Zeisler H, Brancher-Todesca D, et al. Shortterm effects of topical testosterone in vulvar lichen sclerosus. *Obstet Gynecol*. 1997;89(2):297–299.

31. Hansen J, Eckert L, Mlytz H. Sex hormones and carcinoma of the larynx in women. *Arch Klin Exp Ohren Nasen Kehlkopfheilkd.* 1969;193(3):277–286.
32. Slayden SM. Risks of menopausal androgen supplementation. *Semin Reprod Endocrinol.* 1998;16(2): 145–152.
33. Need AG, Durbridge TC, Nordin BE. Anabolic steroids in postmenopausal osteoporosis. *Wien Med Wochenschr.* 1993;143(14–15):392–395.
34. Petit JC, Klein T, Rodier D. Hormone therapy for advanced breast cancer with drostanolone propionate. *Bull Cancer.* 1971;58(4):511–522.
35. Wardle PG, Whitehead MI. Non reversible and wide ranging voice changes after treatment with danazol. *Brit Med J.* 1983;287:540.
36. Gelfand MM, Witta B. Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941–1996. *Clin Ther.* 1997;19(3):383–404; discussion 367–368.
37. Abitbol J, Abitbol B. [The voice and menopause: the twilight of the divas.] *Contracep Fertil Sex.* 1998;26(9): 649–655.
38. Mercaitis PA, Peaper RE, Schwartz PA. Effect of danazol on vocal pitch: a case study. *Obstet Gynecol.* 1985; 65:131–135.
39. Sorgo W, Zachmann M. [Virilization caused by methandrostenolone-containing cream in prepubertal girls.] *Helv Paediatric Acta.* 1982;37(4):401–406.
40. Abitbol J, Abitbol P, Abitbol B. Sex hormones and the female voice. *J Voice.* 1999;13(3):424–446.
41. Dordain M. Étude statistique de l'influence des contraceptifs hormonaux sur la voix. *Folia Phoniatr.* 1972; 24:86–96.
42. Pahn V, Goretzlehner G. Stimmstörungen durch hormonale Kontrazeptiva. *Zentralb Gynakol.* 1978;100: 341–346.
43. Schiff M. The “pill” in otolaryngology. *Trans Am Acad Ophthalmol Otolaryngol.* 1968;72:76–84.
44. Brodnitz F. Medical care preventive therapy. In Lawrence V, ed. *Transcripts of the Seventh Annual Symposium: Care of the Professional Voice.* New York, NY: The Voice Foundation; 1978:3:86.
45. Bausch J. Effects and side-effects of hormonal contraceptives in the region of the nose, throat and ear. [In German]. *HNO.* 1983;31(12):409–414.



46. Could contraceptives with progestational effect cause voice change? [In Dutch]. *Ned Tijdschr Geneeskd*. 1975; 119(44):1726–1727.
47. Krahulec I, Urbanova O, Simko S. [Voice changes during hormonal contraception.] [In Czech]. *Cesk Otolaryngol*. 1977;26(4):234–237.
48. Wendler J. Cyclicly dependent variations in efficiency of the voice and its influencing by ovulation inhibitors. [In German]. *Folia Phoniatr (Basel)*.1972;24(4):259–277.
49. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short-term administration of aerolized recombinant human deoxyribonuclease in patients with cystic fibrosis. *Am Rev Respir Dis*. 1993;148:145–151.
50. James IM, Griffith DN, Pearson RM, Newbury P. Effect of oxprenolol on stage-fright in musicians. *Lancet*. 1977;2:952–954.
51. Brantigan CO, Brantigan TA, Joseph N. Effect of beta blockade and beta stimulation on stage fright. *Am J Med*. 1982;72(1):88–94.
52. Lyskowski JC, Dunner FJ. Hoarseness and tricyclic antidepressants. *Am J Psychiatry*. 1980;137:636.
53. Rhoads JH, Lowell SH, Hedgepeth EM. Hoarseness and aphonia as a side effect of tricyclic antidepressants. *Am J Psychiatry*. 1979;136:1599.
54. Vogel D, Carter J. *The Effects of Drugs on Communication Disorders*. San Diego, CA: Singular Publishing Group; 1995:29–135.
55. Schatzberg A, Cole J. *Manual of Clinical Psychopharmacology*. 2nd ed. Washington, DC: APA Press; 1991:40, 50, 55, 58, 66, 68, 69, 72, 73–77, 110–125, 158–165, 169– 177, 185–227, 313–348.
56. Sataloff RT, Mandel S, Caputo Rosen D. Neurological disorders affecting the voice in performance. In: Sataloff RT, ed. *Professional Voice: The Science and Art of Clinical Care*. 2nd ed. San Diego, CA: Singular Publishing Group; 1997:479–498.
57. US Food and Drug Administration. FDA proposes labeling and manufacturing standards for all dietary supplements. *FDA News*. March 7, 2003. [http://www.fda.gov/bbs/topics/NEWS/2003/NEW\\_00876.html](http://www.fda.gov/bbs/topics/NEWS/2003/NEW_00876.html).
58. Ernst E, Pittler MH. Herbal medicine. *Med Clin North Am*. 2002;86(1):149–161.
59. Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systemic review and meta-analysis. *J Clin Psychopharmacol*. 2000;20(1):84–89.

60. Volz HP, Kieser N. Kava-kava extract. WS 1490 vs. placebo in anxiety disorders—a randomized placebo controlled 25-week outpatient trial. *Pharmacopsychiatry*. 1997;30(1):1–5.
61. Escher N, Desmeules J, Giostra E, Gilles M. Hepatitis associated with Kava, an herbal remedy for anxiety. *Br Med J*. 2001;322:139.
62. Shaver K. Liver toxicity with Kava. *Pharm Lett/Prescrib Lett*. 2001;18:180115. <http://www.pharmacistsletter.com>; <http://www.prescribersletter.com>.
63. Murray MT. *The Healing Power of Herbs*. Rocklin, CA: Prima Publishing; 1995.
64. Gilbert J. Ginkgo biloba. *Neurology*. 1997;48:1137.
65. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas with chronic Ginkgo biloba ingestion. *Neurology*. 1996;46:1775–1776.
66. Fesseden JN, Wittenborn WW, Clarke L. Ginkgo biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. *Am Surg*. 2001;67:33–35.
67. Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract on pancreatic beta-cell function in response to glucose loading in normal glucose tolerant individuals. *J Clin Pharmacol*. 2000;40(6):647–654.
68. Gregory BJ. A seizure associated with Ginkgo biloba? *Ann Intern Med*. 2001;134(4):324.
69. Ondrizek RR, Chan PJ, Patton WC, King A. Inhibition of human sperm motility by specific herbs used in alternative medicines. *J Assist Reprod Genet*. 1999;16: 87–91.
70. Jellin MJ, Gregory BJ, Patz S, et al. *Natural Medicine Comprehensive Data Base*. 4th ed. Stockton, CA: Therapeutic Research Factory; 2002:589.
71. Brinkeborn RN, Shah DV, Degenring FH. Echinaforce and other Echinacea fresh plant preparations in the treatment of the common cold. A randomized, placebo controlled, double-blind clinical trial. *Phytomedicine*. 1999;6:1–6.
72. Giles JT, Palat CT III, Chien SH, et al. Evaluation of echinacea for the treatment of the common cold. *Pharmacotherapy*. 2000;20(6):690–697.
73. Bruss K, ed. *The American Cancer Society Guide to Complementary and Alternative Cancer Methods Handbook*. Atlanta, GA: American Cancer Society; 2000:273.

74. Kim HL, Streltzer J, Goebert D. St. John's wort for depression: a meta-analysis of well-defined clinical trials. *J Nerv Ment Dis.* 1999;187:532–538.
75. Brown TM. Acute St. John's wort toxicity. *Am J Emerg Med.* 2000;18:231–232.
76. Miller LG. Herbal medicinals: selective clinical considerations focusing on known or potential drug-herb interactions. *Arch Int Med.* 1998;158:2200–2201.
77. Doyle H, Kargin N. Herbal stimulant containing ephedrine has also caused psychosis. *Br J Med.* 1996; 313(7059):756.
78. Haller CA, Benowitz ML. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. *N Eng J Med.* 2000;343(25):1833–1838.
79. Meenan KD, White MK, Romak J, Sataloff RT. Common vocal remedies: What are they and do they really work? *J Singing.* 2016;73(2) In print.
80. Tilburt J, Kaptchuk T. Herbal medicine research and global health: an ethical analysis. *Bull World Health Org.* 2008;86(8):594–599.
81. Angell M, Kassirer JP. Alternative medicine: the risks of untested and unregulated remedies. *N Eng J Med.* 1998;339(12):839–841.
82. Cirigliano M, Sun A. Advising patients about herbal therapies. *JAMA.* 1998;18:1565–1566.
83. Fong HS. Integration of herbal medicine into modern medical practices: issues and prospects. *Integr Cancer Ther.* 2002;3:287–293.
84. Traditionalmedicinals.com [Internet]. Sebastopol, CA: Traditional Medicinals; 2013. <http://www.traditionalmedicinals.com/products/throat-coat/>. Accessed November 12, 2015.
85. Brinckmann J, Sigwart H, van Houten Taylor L. Safety and efficacy of a traditional herbal medicine (Throat Coat) in symptomatic temporary relief of pain in patients with acute pharyngitis: a multicenter, prospective, randomized, double-blinded, placebocontrolled study. *J Altern Complement Med.* 2003;9(2): 285–298.
86. Murray M. Glycyrrhiza globra (Licorice). In: Pizzorno JE, Murray MT, eds. *Textbook of Natural Medicine.* 4th ed. St. Louis: Elsevier/Churchill Livingstone; 2013: 804–812.
87. Izzo A, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. *Int J Cardiol.* 2005;98:1–14.

88. Kamei J, Nakamura R, Ichiki H, Kubo M. Antitussive principles of *Glycyrrhizae radix*, a main component of the Kampo preparations Bakumondo-to (Mai-mendong-tang). *Eur J Pharmacol.* 2003;469(1-3):159-163.
89. Omar HR, Komarova I, El-Ghonemi M, et al. Licorice abuse: time to send a warning message. *Ther Adv Endocrinol Metab.* 2012;3(4):125-138.
90. Zick SM, Sen A, Feng Y, Green J, Olatunde S, Boon H. Trial of Essiac to ascertain its effect in women with breast cancer (TEA-BC). *J Altern Complement Med.* 2006;12(10):971-980.
91. Cassileth B. Essiac. *Oncology (Williston Park).* 2011; 25(11):1098-1099.
92. Benbassat N, Kostova B, Nikolova I, Rachev D. Development and evaluation of novel lozenges containing marshmallow root extract. *Pak J Pharm Sci.* 2013; 26(6):1103-1107.
93. Marshmallow: *Althaea officinalis*. In: Fleming T, ed. *PDR for Herbal Medicine.* 4th ed. Montvale, NJ: Medical Economics Company; 2000:505-506.
94. Entertainers-secret.com [Internet]. Carmel, IN: Entertainer's Secret; 2014. <http://www.entertainers-secret.com/>. Accessed November 12, 2015.
95. Roy N, Tanner K, Gray SD, Blomgren M, Fisher KV. An evaluation of the effects of three laryngeal lubricants on phonation threshold pressure (PTP). *J Voice.* 2003;17(3):331-342.
96. Vocaleze.com [Internet]. Colorado Springs, CO: Vocaleze; 2014. <http://vocaleze.com/index.php/>. Accessed November 12, 2015.
97. Terrell B, Fennell A. Oshá (Bear Root): *Ligusticum porteri* J.M. Coult. & Rose var. *porteri*. *NPJ.* 2009;10(2): 110-117.
98. Leon A, Toscano RA, Tortoriello, J, Delgado G. Phthalides and other constituents from *Ligusticum porteri*; sedative and spasmolytic activities of some natural products and derivatives. *Nat Prod Res.* 2011; 25(13):1234-1242.
99. Ginger: *Zingiber officinale*. In: Fleming T, ed. *PDR for Herbal Medicine.* 4th ed. Montvale, NJ: Medical Economics Company; 2000:334-341.
100. Ojewole JA. Analgesic, anti-inflammatory and hypoglycaemic effects of ethanol extracts of *Zingiber officinale* (Roscoe) rhizomes (*Zingiberaceae*) in mice and rats. *Phytother Res.* 2006;20(9):764-772.

101. Terry R, Posadzki P, Watson LK, Ernst E. The use of ginger (*Zingiber officinale*) for the treatment of pain: a systematic review of clinical trials. *Pain Med.* 2011; 12(12):1808–1818.
102. Chang JS, Wang KC, Yeh CF, Shieh DE, Chiang LC. Fresh ginger (*Zingiber officinale*) has anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines. *J Ethnopharmacol.* 2013; 145(1):145–151.
103. Malu SP, Obochi GO, Tawo EN, Nyong BE. Antibacterial activity and medicinal properties of ginger (*Zingiber officinale*). *Global J Pure Appl Sci.* 2009;15(3): 365–368.
104. Karsch-Völk M, Barrett B, Kiefer D, Bauer R, ArdjomanWoelkart K, Linde K. Echinacea for preventing and treating the common cold. *Cochrane Acute Respiratory Infections Group.* 2014. doi:10.1002/14651858. CD000530.pub3
105. Wagh VD. Propolis: A wonder bees product and its pharmacologic potentials. *Adv Pharmacol Sci.* 2013. doi:10.1155/2013/308249
106. Hwu YJ, Lin FY. Effectiveness of propolis on oral health: a systematic review. *JBI Database System Rev Implement Rep.* 2013;11(5):28–61.
107. Thayers.com [Internet]. Westport, CT: Thayers Natural Remedies; 2014. <http://www.thayers.com/>. Accessed November 12, 2015.
108. Vocalzone.com [Internet]. Broadstone, England: Kestrel Medical Ltd. <http://www.vocalzone.com/>. Accessed November 12, 2015.
109. Pimentel M, Bonorris GG, Chow EJ, Lin HC. Peppermint oil improves the manometric findings in Diffuse Esophageal Spasm. *J Clin Gastroenterol.* 2001;1:27–31.
110. Klinger B, Chaudhary S. Peppermint Oil. *Am Fam Physician.* 2007;7:1027–1030.
111. Wells LK. Evidence-based herbal medicine. *Dental Abstracts.* 2012;57(6):305–307.
112. Peppermint: *Mentha piperita*. In: Fleming, T, ed. *PDR for Herbal Medicine.* 4th ed. Montvale, NJ: Medical Economics Company; 2000:580–583.
113. de Sousa AAS, Soares PMG, de Almeida ANS, Maia AR, de Souza EP, Assreuy AMS. Antispasmodic effect of *Mentha piperita* essential oil on tracheal smooth muscle of rats. *J Ethnopharmacol.* 2010;130(2):433–436.

114. Su S, Duan J, Chen T, et al. Frankincense and myrrh suppress inflammation via regulation of the metabolic profiling and the MAPK signaling pathway. *Sci Rep*. 2015;13668. doi:10.1038/srep13668.
115. Cheng YW, Cheah KP, Lin CW, et al. Myrrh mediates haem oxygenase-1 expression to suppress the lipopolysaccharide-induced inflammatory response in RAW264.7 macrophages. *J Pharm Pharmacol*. 2011; 63(9):1211–1218.
116. Su S, Wang T, Duan JA, et al. Anti-inflammatory and analgesic activity of different extracts of *Commiphora myrrha*. *J Ethnopharmacol*. 2011;134(2):251–258.
117. Myrrh: *Commiphora molmol*. In: Fleming, T, ed. *PDR for Herbal Medicine*. 4th ed. Montvale, NJ: Medical Economics Company; 2000:534–536.
118. Vitavocalhealth.com [Internet]. VitaVocal Health. <http://www.vitavocalhealth.com/product/vitavocal-throat-voice-enhancer/>. Accessed November 12, 2015.
119. Ginseng: *Panax ginseng*. In: Fleming, T, ed. *PDR for Herbal Medicine*. 4th ed. Montvale, NJ: Medical Economics Company; 2000:346–349.
120. Scaglione F, Cattaneo G, Alessandria M, Cogo R. Efficacy and safety of the standardized Ginseng extract G115 for potentiating vaccination against the influenza syndrome and protection against the common cold [corrected]. *Drugs Exp Clin Res*. 1996;22(2):65–72.
121. McElhaney JE, Gravenstein S, Cole SK, et al. A placebocontrolled trial of a proprietary extract of North American ginseng (CVT-E002) to prevent acute respiratory illness in institutionalized older adults. *J Am Geriatr Soc*. 2004;52(1):13–19.
122. McElhaney JE, Goel V, Toane B, Hooten J, Shan JJ. Efficacy of COLD-fX in the prevention of respiratory symptoms in community-dwelling adults: a randomized, double-blinded, placebo-controlled trial. *J Altern Complement Med*. 2006;12(2):153–157.
123. Vohra S, Johnston BC, Laycock KL, et al. Safety and tolerability of North American ginseng extract in the treatment of pediatric upper respiratory tract infection: a phase II randomized, controlled trial of 2 dosing schedules. *Pediatrics*. 2008;122(2):e402–410.
124. Saveritemedical.com [Internet]. Brooklyn, NY: Save Rite Medical. <http://www.saveritemedical.com/product/sprouts-voice-formula-for-singers-a->

- voiceremedy-for-hoarsness-laryngitis-and-expectorant .html. Accessed November 12, 2015.
125. Slippery elm: *Ulmus rubra*. In: Fleming T, ed. PDR for Herbal Medicine. 4th ed. Montvale, NJ: Medical Economics Company; 2000:697.
126. Fennel: *Foeniculum vulgare*. In: Fleming T, ed. PDR for Herbal Medicine. 4th ed. Montvale, NJ: Medical Economics Company; 2000:302–304.
127. Horseradish: *Armor acta rusticana*. In: Fleming T, ed. PDR for Herbal Medicine. 4th ed. Montvale, NJ: Medical Economics Company; 2000:408–409.
128. Thyme: *Thymus vulgaris*. In: Fleming T, ed. PDR for Herbal Medicine. 4th ed. Montvale, NJ: Medical Economics Company; 2000:761–762.
129. Celery: *Apium graveolens*. In: Fleming T, ed. PDR for Herbal Medicine. 4th ed. Montvale, NJ: Medical Economics Company; 2000:172–174.
130. Molan PP, Rhodes T. Honey: A biologic wound dressing. *Wounds*. 2015;27(6):141–151.
131. Al-Waili NS, Boni BS. Natural honey lowers plasma prostaglandin concentrations in normal individuals. *J Med Food*. 2004;6(2):129–133.
132. Al-Waili NS. Effects of honey on the urinary total nitrite and prostaglandin concentration. *Int Urol Nephrol*. 2005;37(1):107–111.
133. Timm M, Bartlet S, Hansen EW. Immunomodulatory effects of honey cannot be distinguished from endotoxin. *Cytokine*. 2008;42(1):113–120.
134. Paul IM, Beiler J, McMonagle A, Shaffer ML, Duda L, Berlin CM. Effect of honey, dextromethorphan, and no treatment on nocturnal cough and sleep quality for coughing children and their parents. *JAMA Pediatr*. 2007;161(12):1140–1146.
135. Shadkam MN, Mozaffari-Khosravi H, Mozayan MR. A comparison of the effect of honey, dextromethorphan, and diphenhydramine on nightly cough and sleep quality in children and their parents. *J Altern Complement Med*. 2010;16(7):787–793.
136. Raessi MA, Aslani J, Raessi N, Gharaie H, Zarchi AAK, Raessi F. Honey plus coffee versus systemic steroid in the treatment of post-infectious cough: a randomized controlled trial. *Prim Care Respir J*. 2013; 22:325-330.
137. Henatsch D, Wesseling F, Kross KW, Stokroos RJ. Honey and beehive products in otorhinolaryngology: a narrative review. *Clin Otolaryngol*. 2016;41(5):519–531.

138. Cayenne: *Capsicum* species. In: Fleming T, ed. *PDR for Herbal Medicine*. 4th ed. Montvale, NJ: Medical Economics Company; 2000:165–168.
139. Al-Abri SA, Kearney T. Baking soda misuse as a home remedy: case experience of the California Poison Control System. *J Clin Pharm Ther*. 2014;39(1):73–77.
140. Pakrokh GP. The extraction process optimization of antioxidant polysaccharides from Marshmallow (*Althaea officinalis* L.) roots. *Int J Biol Macromol*. 2015; 75:51–57. doi:10.1016/j.ijbiomac.2014.11.047.
141. Limb M, Connor A, Pickford M, et al. Scintigraphy can be used to compare delivery of sore throat formulations. *Int J Clin Pract*. 2009;63(4):606–612.
142. Tanner K, Roy N, Merrill RM, Elstad M. The effects of three nebulized osmotic agents in the dry larynx. *J Speech Lang Hear Res*. 2007;50(3):635–646.
143. Verdolini K, Titze IR, Fennell A. Dependence of phonatory effort on hydration level. *J Speech Hear Res*. 1994;37(5):1001–1007.
144. Verdolini-Marston K, Titze IR, Druker DG. Changes in phonation threshold pressure with induced conditions of hydration. *J Voice*. 1990;4(2):142–151.
145. Solomon NP, Glaze LE, Arnold RR, van Mersbergen M. Effects of a vocally fatiguing task and systemic hydration on men’s voices. *J Voice*. 2003;17(1):31–46.
146. Solomon NP, DiMattia MS. Effects of a vocally fatiguing task and systemic hydration on phonation threshold pressure. *J Voice*. 2000;14(3):341–362.
147. Tanner K, Roy N, Merrill RM, et al. Nebulized isotonic saline versus water following a laryngeal dessication challenge in classically trained sopranos. *J Speech Lang Hear Res*. 2010;53(6):1555–1566.
148. Tanner K, Fujiki RB, Dromey C, et al. Laryngeal desiccation challenge and nebulized isotonic saline in healthy male singers and nonsingers: effects on acoustic, aerodynamic, and self-perceived effort and dryness measures [published online September 26, 2015]. *J Voice*. 2016;30(6):670–676.
149. Hunter E, Tanner K, Smith M. Gender differences affecting vocal health of women in vocally demanding careers. *Logoped Phoniatr Vocol*. 2011;36(3):128–136.
150. Sabar R, Kaye AD, Frost, EA. Perioperative considerations for the patient taking herbal medicines. *Heart Dis*. 2001;3(2):87–96.



151. Surow JB, Lovetri J. "Alternative medical therapy" use among singers: prevalence and implications for the medical care of the singer. *J Voice*. 2000;14(3):398–409.

## فصل ١٨

1. Othmer E, Sieglind SC. *The Clinical Interview Using DSM-IV*. Vol 1. Washington, DC: American Psychiatric Press; 1994:252–259.
2. Bernstein JG. *Handbook of Drug Therapy in Psychiatry*. St Louis, MO: Mosby; 1995:370–371.
3. Bazire S, Benefield WH Jr, William H. *Psychologic Drug Directory 1997–8*. West Orange, NJ: Quay Books; 1997: 217–236.
4. Bernstein JG. *Handbook of Drug Therapy in Psychiatry*. St Louis, MO: Mosby; 1995:353.
5. Bernstein JG. *Handbook of Drug Therapy in Psychiatry*. St Louis, MO: Mosby; 1995:546.
6. Bernstein JG. *Handbook of Drug Therapy in Psychiatry*. St Louis, MO: Mosby; 1995:384.
7. Stahl SM. *Psychopharmacology of Antidepressants*. London, England: Dunitz Ltd; 1997:101–108.
8. Sataloff RT, Castell DO, Sataloff DM, Sataloff J. Reflux and other gastroenterologic conditions that may affect the voice. In: Sataloff RT, ed. *Professional Voice: The Science and Art of Clinical Care*. 2nd ed. San Diego, CA: Singular Publishing Group; 1997:319–329.
9. Sataloff RT, Castell DO, Katz PO, Sataloff DM. *Reflux Laryngitis and Related Disorders*. San Diego, CA: Singular Publishing Group; 1999.
10. Bernstein J. *Handbook of Drug Therapy in Psychiatry*. St Louis, MO: Mosby; 1995:380–381.
11. Canter TG, Korek JS. Central nervous system reaction to histamine-2 receptor blockers. *Ann Intern Med*. 1991;14:1027–1034.
12. Rampello L, Nicoletti G. The H2-antagonist therapy withdraw syndrome. *Medicina (Firenze)*. 1990;10(3): 299–306.
13. Bernstein JG. *Handbook of Drug Therapy in Psychiatry*. St Louis, MO: Mosby; 1995:346.

14. Bazire S, Benefield WH Jr, William H. Psychologic Drug Directory 1997–8. West Orange NJ: Quay Books; 1997: 179.
15. Bazire S, Benefield WH Jr, William H. Psychologic Drug Directory 1997–8. West Orange, NJ: Quay Books; 1997: 166.
16. Bernstein JG. Handbook of Drug Therapy in Psychiatry. St Louis, MO: Mosby; 1995:359.

## فصل ۱۹

1. Neuenschwander MC, Pribitkin EA, Sataloff RT. Botulinum toxin in otolaryngology: a review of its actions and opportunities for use. Ear Nose Throat J. 2000;79: 788–801.
2. Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope. 2001;111: 218–226.
3. Schantz EJ, Johnson EA. Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med. 1997;40:317–327.
4. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12:924–927.
5. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044–1049.
6. Fischer A. FDA approves Botox Cosmetic to improve the appearance of crow's feet lines. FDA News Release; September 11, 2013. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm367662.htm>. Accessed on January 2, 2016.
7. Allergan, 2014. <http://www.botox.com/>. Accessed December 30, 2015.
8. Tsui JK. Botulinum toxin as a therapeutic agent. Pharmacol Ther. 1996;72:13–24.
9. Simpson LL. Clinically relevant aspects of the mechanism of action of botulinum neurotoxin. J Voice. 1992; 6:358–364.
10. Mezaki T, Kaji R, Kohara N, et al. Comparison of therapeutic efficacies of Type A and F botulinum toxins for blepharospasm. Neurology. 1995;45:506–508.
11. NIH Consensus Development Panel on Clinical Use of Botulinum Toxin. Botulinum toxin. J Voice. 1992;6: 394–400.
12. Holland RL, Brown MC. Nerve growth in botulinum toxin poisoned muscles. Neuroscience. 1981;6:1167–1179.

13. Duchen LW, Strich SJ. The effects of botulinum toxin on the pattern of innervation of skeletal muscle in the mouse. *Q J Exp Physiol.* 1968;53:84–89.
14. Duchen LW. Changes in the electron microscopic structure of slow and fast skeletal muscle fibers of the mouse after local injection of botulinum toxin. *J Neurol Sci.* 1971;14:61–74.
15. Castellanos PF, Gates GA, Esselman G, et al. Anatomic considerations in botulinum toxin Type A therapy for spasmodic dysphonia. *Laryngoscope.* 1994;104:656–662.
16. Wong DL, Adams SG, Irish JC, et al. Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia. *J Otolaryngol.* 1995;24:209–216.
17. Biglan AW, Gonnering R, Lockhart LB, et al. Absence of antibody production in patients treated with botulinum A toxin. *Am J Ophthalmol.* 1986;101:232–235.
18. Ipsen Biopharmaceuticals, 2015. [http://www.dysport.com/welcome/downloads/Dysport%20Full%20 Prescribing%20Information.pdf](http://www.dysport.com/welcome/downloads/Dysport%20Full%20Prescribing%20Information.pdf). Accessed January 2, 2016.
19. Merz Pharmaceuticals, 2015. <http://www.xeomin.com/wp-content/uploads/xeomin-full-prescribinginformation.pdf>. Accessed January 2, 2016.
20. Solstice Neurosciences, 2010. [http://www.myobloc.com/hp\\_about/PI\\_5-19-10.pdf](http://www.myobloc.com/hp_about/PI_5-19-10.pdf). Accessed January 2, 2016.
21. Sloop RR, Cole BA, Escutin RO. Reconstituted botulinum toxin Type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. *Neurology.* 1997;48:249–253.
22. Gartlan MG, Hoffman HT. Crystalline preparation of botulinum toxin Type A (Botox): degradation in potency with storage. *Otolaryngol Head Neck Surg.* 1993;108:135–140.
23. Warrick P, Dromey C, Irish J, et al. Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection. *Laryngoscope.* 2000;110: 1366–1376.
24. Kendall K, Leonard R. Interarytenoid muscle Botox injection for treatment of adductor spasmodic dysphonia with vocal tremor. *J Voice.* 2011;25(1):114–119.
25. Hertegard S, Granqvist S, Lindestad P. Botulinum toxin injections for essential voice tremor. *Ann Otol Rhinol Laryngol.* 2000;109:204–209.

26. Merati A, Heman-Ackah Y, Abaza M, Altman K, Sulica L, Belamowicz S. Academy committee review: common movement disorders affecting the larynx: a report from the Neurolaryngology Committee of the AAOHNS. *Otolaryn Head Neck Surg.* 2005;133(5):654–665.
27. Maronia N, Robinson L, Waugh P, Hillerl A. Tremor laryngeal dystonia: treatment of the lateral cricoarytenoid muscle. *Ann Otol Rhinol Laryngol.* 2004;113(5): 349–355.
28. Justicz N, Hapner E, Josephs J, Boone B, Jinnah H, Johns M. Comparative effectiveness of propranolol and botulinum for the treatment of essential voice tremor. *Laryngoscope.* 2016;126(1):113–117.
29. Mauriello JA Jr, Dhillon S, Leone T, et al. Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years. *Br J Ophthalmol.* 1996; 80:1073–1076.
30. Jordan DR, Patrinely JR, Anderson RL, Thiese SM. Essential blepharospasm and related dystonias. *Surv Ophthalmol.* 1989;34:123–132.
31. Taylor JD, Kraft SP, Kazdan MS, et al. Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study. *Can J Ophthalmol.* 1991;26:133–138.
32. Price J, Farish S, Taylor H, O'Day J. Blepharospasm and hemifacial spasm: randomized trial to determine the most appropriate location for botulinum toxin injections. *Ophthalmology.* 1997;104:865–868.
33. Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. *Mov Disord.* 1987;2:237–254.
34. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. *J Neurol Neurosurg Psychiatry.* 1990;53:633–639.
35. Biglan AW, May M, Bowers RA. Management of facial spasm with Clostridium botulinum toxin, Type A (Oculinum). *Arch Otolaryngol Head Neck Surg.* 1988; 114:1407–1412.
36. Ababneh O, Cetinkaya A, Kulwin D. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. *Clin Exper Ophthal.* 2014;42(3):254–261.

37. Bentvoglio A, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. *Eur J Neurol.* 2009;16(3):392–398.
38. Cultrara A, Chitkara A, Blitzer A. Botulinum toxin injections for the treatment of oromandibular dystonia. *Oper Tech Otolaryngol Head Neck Surg.* 2004;15(2): 97–102.
39. Blitzer A, Brin MF, Greene PE, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. *Ann Otol Rhinol Laryngol.* 1989;98:93–96.
40. Pedemonte C, Perez Gutierrez H, Gonzalez E, Vargas I, Lazo D. Use of Onabotulinumtoxin A in posttraumatic oromandibular dystonia. *J Oral Max Surg.* 2015;73(1):152–157.
41. Erdal J, Werdelin L, Prytz S, Fuglsang A, Moller E. Botulinum toxin treatment of patients with oromandibular dystonia. *Ugeskr Laeger.* 2000;162:6567–6571.
42. Tan E, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. *Neurol.* 1999;53:2102–2107.
43. Ramirez-Castaneda J, Jankovic J. Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. *Toxicon.* 2014;90:344–348.
44. Papapetropoulos S, Baez S, Zitser J, Sengun C, Singer C. Retrocollis: classification, clinical phenotype, treatment outcomes and risk factors. *Eur Neurol.* 2008;59: 71–75.
45. Tomczak K, Rosman N. Torticollis. *J Child Neurol.* 2013;28:365–378.
46. Chan J, Brin M, Fahn S. Idiopathic cervical dystonia: clinical characteristics. *Mov Disord.* 1991;6(2):119–126.
47. Jankovic J. Botulinum toxin therapy for cervical dystonia. *Neurotox Res.* 2006;9(2,3):145–148.
48. Borodic GE, Joseph M, Fay L, et al. Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. *Head Neck.* 1990;12: 392–398.
49. Coulson S, O'Dwyer N, Adams R, Croxson G. Expression of emotion and quality of life after facial nerve paralysis. *Otol Neurotol.* 2004;25:1014–1019.
50. Bikhazi N, Maas C. Refinement in the rehabilitation of the paralyzed face using botulinum toxin. *Otolaryngol Head Neck Surg.* 1997;117:303–307.

51. Filipo R, Spahiu I, Covelli E, Nicastrì G, Bertoli G. Botulinum toxin in the treatment of facial synkinesis and hyperkinesis. *Laryngoscope*. 2012;122(2):266–270.
52. Borodic GE, Pearce LB, Cheney M, et al. Botulinum A toxin for treatment of aberrant facial nerve regeneration. *Plast Reconstr Surg*. 1993;91:1042–1045.
53. Armstrong M, Mountain R, Murray J. Treatment of facial synkinesis and facial asymmetry with botulinum toxin A following facial nerve palsy. *Clin Otolaryngol Allied Sci*. 1996;21:15–20.
54. May M, Croxson GR, Klein SR. Bell's palsy: management of sequelae using EMG rehabilitation, botulinum toxin, and surgery. *Am J Otol*. 1989;10:220–229.
55. Salles A, Toledo P, Ferreira M. Botulinum toxin injection in long-standing facial paralysis patients: improvement of facial symmetry observed up to 6 months. *Aesthetic Plast Surg*. 2009;33(4):582–590.
56. Carruthers A, Kiene K, Carruthers J. Botulinum A exotoxin use in clinical dermatology. *J Am Acad Dermatol*. 1996;34:788–797.
57. Keen M, Blitzer A, Aviv J, et al. Botulinum toxin A for hyperkinetic facial lines: results of a double-blind, placebo-controlled study. *Plast Reconstr Surg*. 1994;94:94–99.
58. Pribitkin EA, Greco TM, Goode RL, Keane WM. Patient selection in the treatment of glabellar wrinkles with botulinum toxin Type A injection. *Arch Otolaryngol Head Neck Surg*. 1997;123:321–326.
59. Lowe NJ, Maxwell A, Harper H. Botulinum A exotoxin for glabellar folds: a double-blind, placebocontrolled study with an electromyographic injection technique. *J Am Acad Dermatol*. 1996;35:569–572.
60. Blitzer A, Brin MF, Keen MS, Aviv JE. Botulinum toxin for the treatment of hyperfunctional lines of the face. *Arch Otolaryngol Head Neck Surg*. 1993;119:1018–1022.
61. Blitzer A, Komisar A, Baredes S, et al. Voice failure after tracheoesophageal puncture: management with botulinum toxin. *Otolaryngol Head Neck Surg*. 1995;113: 668–670.
62. Blitzer A, Brin MF. Use of botulinum toxin for diagnosis and management of cricopharyngeal achalasia. *Otolaryngol Head Neck Surg*. 1997;116:328–330.

63. Ahsan S, Meleca R, Dworkin J. Botulinum toxin injection of the cricopharyngeus muscle for the treatment of dysphagia. *Otolaryngol Head Neck Surg.* 2000;122(5): 691–695.
64. Kuhn M, Belafsky P. Management of cricopharyngeus muscle dysfunction. *Otolaryngol Clin North Am.* 2013; 46(6):1087–1099.
65. Moerman M. Cricopharyngeal Botox injection: indications and technique. *Curr Opin Otolaryngol Head Neck Surg.* 2006;14:431–436.
66. Zaninotto G, Marchese R, Briani C, et al. The role of botulinum toxin injection and upper esophageal sphincter myotomy in treating oropharyngeal dysphagia. *J Gastrointest Surg.* 2004;8:997–1006.
67. Kelly E, Koszewski I, Jaradeh S, et al. Botulinum toxin injection for the treatment of upper esophageal sphincter dysfunction. *Ann Otol Rhinol Laryngol.* 2013; 122:100–108.
68. Barbanti P, Egeo G, Fofi L, Aurilia C, Piroso S. Rationale for use of onabotulinum toxin A in chronic migraine. *Neurol Sci.* 2015;36(1):S29–S32.
69. Zhalil M, Safar H, Quarshie V, Ahmed F. Prospective analysis of the use of onabotulinumtoxin A in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK. *J Headache Pain.* 2014;15:54.
70. Massumi K, Thompson N, Krieger J, Tepper S. Effect of onabotulinumtoxin A on depression in chronic migraine. *J Head Face Pain.* 2015;55(9):1218–1224.
71. Diener H, Dodick D, Goadsby P, et al. Chronic migraine—classification, characteristics and treatment. *Nat Rev Neurol.* 2012;8(3):162–171.
72. Burstein R, Zhang X, Levy D, et al. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. *Cephalgia.* 2014;34(11):853–869.
73. Diener H, Holle D, Dodick D. Treatment of chronic migraine. *Curr Pain Headache.* 2011;15(1):64–69.
74. Aoki K. Review of a proposed mechanism for the antinociceptive action of botulinum tons type A. *Neurotoxicology.* 2005;26:785–793.
75. Grazi L, Usai S. Onabotulinum toxin A for chronic migraine treatment: an Italian experience. *Neurolog Sci.* 2015;36(1):s33–s35.

76. Lakraj A, Moghimi N, Jabbari B. Sialorrhea: anatomy, pathophysiology, and treatment with emphasis on the role of botulinum toxins. *Toxins*. 2013;5(5):1010–1031.
77. Formeister E, Dahl J, Rose A. Surgical management of chronic sialorrhea in pediatric patients: 10-year experience from one tertiary care institution. *Int J Ped Otorhinolaryngol*. 2014;78(8):1387–1392.
78. Gomez-Caravaca M, Caceres-Redondo M, HuertasFernandez I, et al. The use of botulinum toxin in the treatment of sialorrhea in parkinsonian disorders. *Neurol Sci*. 2015;36(2):275–279.
79. Schroeder A, Kling T, Huss K, et al. Botulinum toxin type A and B for the reduction of hypersalivation in children with neurological disorders: a focus on effectiveness and therapy adherence. *Neuropediatrics*. 2012; 43(1):27–36.
80. Porte M, Chaleat-Valayer E, Patte K, D’Anjou M, Boulay C, Laffont I. Relevance of intraglandular injections of botulinum toxin for the treatment of sialorrhea in children with cerebral palsy: a review. *Eur J Paed Neurol*. 2014;18(6):649–657.
81. Talmi Y, Finkelstein Y, Zohar Y. Reduction of salivary flow with transdermal scopolamine: a four-year experience. *Otolaryngol Head Neck Surg*. 1990;103:615–618.
82. Mier R, Bachrach S, Lakin R, Barker T, Childs J, Moran M. Treatment of sialorrhea with glycopyrrolate: a double-blind, dose-ranging study. *Arch Pediatr Adolesc Med*. 2000;154:1214–1218.
83. Banerjee K, Glasson C, O’Flaherty S. Parotid and submandibular botulinum toxin A injections for sialorrhea in children with cerebral palsy. *Dev Med Child Neurol*. 2006;48(11):883–887.
84. Gerlinger I, Szalai G, Hollody K, et al. Intraglandular injection of botulinum toxin A in children suffering from excessive salivation. *J Laryngol Otol*. 2007; 121(10):947–951.
85. Lungren M, Halula S, Coyne S, Sidell D, Racadio J, Patel M. Ultrasound-guided botulinum toxin type A salivary gland injection in children for refractory sialorrhea: 10-year experience at a large tertiary children’s hospital. *Ped Neurol*. 2016;54:70–75.



86. Daniel S. Botulinum toxin injection techniques for pediatric sialorrhea. *Oper Tech Otolaryngol Head Neck Surg.* 2015;26(1):42–49.
87. Laccourreya O, Bonan B, Brasnu D, Laccourreya H. Treatment of Frey's syndrome with topical 2% diphemanil methylsulfate (Prantal): a double-blind evaluation of 15 patients. *Laryngoscope.* 1990;100(6):651–653.
88. Hays L. The Frey syndrome: a review and double blind evaluation of the topical use of a new anticholinergic agent. *Laryngoscope.* 1978;88:1796–1824.
89. Guntinas-Lichius O. Management of Frey's syndrome and hypersialorrhea with botulinum toxin. *Facial Plas Surg Clin North Am.* 2003;11(4):503–513.
90. Wang C, Wang C. Preliminary experience with botulinum toxin type A intracutaneous injection for Frey's syndrome. *J Chin Med Assoc.* 2005;68(10):463–467.
91. Pornprasit M, Chintrakam C. Treatment of Frey's syndrome with botulinum toxin. *J Med Assoc Thailand.* 2007;90(11):2397–2402.
92. Arad-Cohen A, Blitzer R. Botulinum toxin treatment for symptomatic Frey's syndrome. *Otolaryngol Head Neck Surg.* 2000;122(2):237–240.
93. Dulguerov P, Quinodoz D, Cosendai G, Piletta P, Lehmann W. Frey syndrome treatment with botulinum toxin. *Otolaryngol Head Neck Surg.* 2000;122(6):821–827.
94. Alshadwi A, Nadershah M, Osborn T. Review article: therapeutic applications of botulinum toxin neurotoxins in head and neck disorders. *Saudi Dent J.* 2015; 27(1):3–11.
95. Chiu A, Cohen J, Burningham A, Andersen P, Davidson B. First bite syndrome: a complication of surgery involving the parapharyngeal space. *Head Neck.* 2002; 24(11):996–999.
96. Ali M, Orloff L, Lustig L, Eisele D. Botulinum toxin in the treatment of first bite syndrome. *Otolaryngol Head Neck Surg.* 2008;139(5):742–743.
97. Ghosh A, Mirza N. First bite syndrome: our experience with intraparotid injections with botulinum toxin type A. *Laryngoscope.* 2016;126(1):104–107.
98. Mikolajczak S, Ludwig L, Grosheva M, Beutner D. First bite syndrome: successful treatment with botulinum toxin A. *Laryngorhinootologie.* 2015;94(8):524–525.

99. Furuta Y, Takahashi H, Tsubuku T, Matsumura M, Fukuda S. A case of first bite syndrome successfully treated with botulinum toxin. *Otolaryngol Head Neck Surg.* 2015;87(11):933–936.
100. Sims J, Suen J. First bite syndrome: case report of 3 patients treated with botulinum toxin and review of other treatment modalities. *Head Neck.* 2013;35(9): E288–E291.
101. Yablon S, Brashear A, Gordon M, et al. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of post stroke spasticity: a pooled data analysis of three clinical trials. *Clin Ther.* 2007;29:683–690.
102. Schulte-Baukloh H, Bigalke H, Miller K, et al. Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. *Int J Urol.* 2008;15:407–415.
103. Mohammadi B, Buhr N, Bigalke H, Krampf K, Denlger R, Kollewe K. A long term follow up of botulinum toxin A in cervical dystonia. *Neurol Res.* 2009;31: 463–466.
104. Muller K, Mix E, Adib F, Dressler D, Benecke R. Prevalence of neutralizing antibodies in patients treated with botulinum toxin type A for spasticity. *J Neural Transm.* 2009;116:579–585.
105. Naumann M, Carruthers A, Carruthers J, et al. Meta analysis of neutralizing antibody conversion with onabotulinumtoxin A across multiple indications. *Mov Disord.* 2010;25:2211–2218.
106. Hatheway CH, Dang C. Immunogenicity of the neurotoxins of *Clostridium botulinum*. In: Jankovic J, Hallett M, eds. *Therapy with Botulinum Toxin*. New York, NY: Marcel Dekker; 1994:93–107.
107. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. *Mov Disord.* 1994;9:213–217.
108. Torres S, Hamilton M, Sanches E, Starovatova P, Gubanova E, Reshetnikova T. Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports. *Clin Cosmet Investig Dermatol.* 2014;7: 11–17.
109. Borodic G. Immunologic resistance after repeated botulinum toxin type A injections for facial rhytides. *Ophthal Plast Reconstr Surg.* 2006;22:239–240.
110. Dressler D, Wohlfahrt K, Meyer-Rogge E, Wiest L, Bigalke H. Antibody induced failure of botulinum toxin A therapy in cosmetic indications. *Dermatol Surg.* 2010;36(4):2182–2187.

111. Stengel G, Bee E. Antibody induced secondary treatment failure in a patient treated with botulinum toxin A for glabellar frown lines. *Clin Interv Aging*. 2011;6: 281–284.
112. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. *Neurology*. 1995; 45:1743–1746.
113. Dressler D, Gessler F, Tacik P, Bigalke H. An enzymelinked immunosorbent assay for detection of botulinum toxin antibodies. *Mov Disord*. 2014;29(10): 1322–1324.
114. Diamant E, Lachmi B, Keren A, et al. Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations. *PloS One*. 2014; 9(1):e87089.
115. Sataloff RT, Heman-Ackah YD, Simpson LL, et al. Botulinum toxin type B for treatment of spasmodic dysphonia: a case report. *J Voice*. 2002;16:422–424.
116. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance and problems with available materials. *Neurology*. 1996;46: 26–29.
117. Tsui JK, Hayward M, Mak EK, Schulzer M. Botulinum toxin type B in the treatment of cervical dystonia: a pilot study. *Neurology*. 1995;45:2109–2110.
118. Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: type B compared with type A. *Neurology*. 1997;49:189–194.
119. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. *Neurology*. 1999;53:1431–1438.
120. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. *Neurology*. 1997;49:701–706.
121. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. *Neurology*. 1999;53: 1439–1446.